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Vurdering av basalcelle karsinom forut for lokal 
fotodynamisk terapi og langtidsresultat etter behandlingen 
 
Avhandlingen er basert på studier som evaluerer diagnostiske metoder av basalcelle 
karsinom (BCC) forut for lokal fotodynamisk terapi (PDT) og langtidsresultat etter 
behandlingen. Vi fant godt samsvar mellom cytologisk og histologisk diagnostikk. 
Informasjon om BCC tykkelse fra stansebiopsier, kunne ikke alltid forutsi hvilke BCC 
som egnet seg for PDT. PDT av små, primære BCC gav få tilbakefall og et godt 
kosmetisk resultat 6 og 10 år etter behandling. 
BCC er den vanligste form for kreft hos mennesker med lys hud og opptrer ofte 
på soleksponerte, kosmetisk utsatte hudområder som i ansiktet. Effektive diagnostiske 
og terapeutiske metoder, som bidrar til å gi et best mulig kosmetisk resultat, er således 
etterspurt. Prøvetakingen for cytologisk diagnostikk påfører huden minimal skade 
sammenlignet med biopsitaking for histologisk undersøkelse, og bør derfor vurderes. 
PDT er en vevsbesparende, minimal-invasiv behandlingsmetode som gir et godt 
kosmetisk resultat og som i økende grad brukes til behandling av BCC. Metoden 
baserer seg på at et lysfølsomt stoff akkumuleres hovedsaklig i de syke cellene. Ved 
belysning med synlig (rødt) lys og tilstedeværelse av oksygen dannes reaktive oksygen 
forbindelser som ødelegger de cellene som har høy konsentrasjon av det lysfølsomme 
stoffet. Tykkelsen av BCC kan påvirke behandlingsresultatet ved PDT. Både middelet 
(aminolevulinsyre, ALA) og lysstrålene som benyttes i behandlingen har begrenset evne 
til å penetrere huden. PDT er derfor i dag anbefalt brukt i behandling av tynne BCC 
(tykkelse < 2.0 mm). Pålitelig informasjon om BCC tykkelse bør derfor foreligge før 
PDT eventuelt velges som behandlingsmetode. Kurettering av BCC og bruk av 
dimethyl sulfoxide (DMSO), som øker penetrasjonen av ALA, kan bidra til å bedre 
behandlingseffekten av PDT. Kunnskap om langtidsresultater er nødvendig for 
evaluering av behandlingsmetoden. 
I den første studien i avhandlingen ble cytologisk diagnose av ikke-melanom 
hudkreft (BCC og aktinske keratoser) sammenliknet med histologisk diagnose 
(”gullstandard”). Hos 41 pasienter med BCC ble 150 cytologiske utstryk 
(skrapeteknikk: n= 100, trykkteknikk: n= 50) undersøkt. Parvise prøver ble tatt fra 
samme lesjon til cytologisk og histologisk undersøkelse. Utstrykene ble farget enten 
med Papanicolaou eller May-Grünwald Giemsa metode. Skrapeteknikken viste 95 % 
samsvar med den histologisk diagnosen. Det var ingen vesentlig forskjell i resultatene 
mellom de to fargemetodene. Trykkteknikken gav mange utstryk med dårlig kvalitet og 
viste diagnostisk samsvar med histologi i 62 %.  
I den andre studien ble 48 BCC hos 43 pasienter undersøkt.  Vi sammenlignet 
mål på BCC tykkelse i parvise prøver fra individuelle lesjoner tatt med stanse- og 
eksisjonsbiopsi. Vi fant liten forskjell i gjennomsnittlig mål på BCC tykkelse i de to 
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gruppene (stansebiopsi1,53 mm, eksisjon 1,67 mm). Ved undersøkelse av enkeltstående 
tynne BCC var det et rimelig godt samsvar mellom de to metodene. BCC tykkelse < 1,0 
mm, målt i en stansebiopsi, ville ved eksisjon mest sannsynlig gi en tykkelse som ligger 
innenfor gjeldende aksepterte grenser for PDT, på cirka 2,0 mm. I tykkere svulster fant 
vi større forskjeller mellom metodene. 
I de to siste studiene ble 44 pasienter med 60 BCC behandlet en eller to ganger 
med kurettering og lokal DMSO-ALA-PDT, og deretter regelmessig kontrollert i 
henholdsvis 6 og 10 år.  Av antall BCC klinisk vurdert som kurert 3 måneder etter 
behandling, forble 81 % sykdomsfrie etter 6 år; 91 % ved PDT gitt to ganger. Ved 
evaluering av alle BCC som fikk behandling, fant vi en helbredelses rate på 75 % etter 
10 år; 90 % ved primær BCC og to PDT behandlinger. Ved kontroll ble BCC påvist i 15 
behandlingsfelt; alle i løpet av de første 3 år etter PDT. Faktorer forbundet med 
behandlingssvikt var mannlig kjønn, BCC lokalisert sentralt i ansikt og på ører, residiv 
BCC (tilbakefall etter tidligere behandling) og kun én PDT behandling. Det kosmetiske 
langtidsresultatet ble vurdert som godt eller utmerket i alle tilfeller. 
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INTRODUCTION 
 
The skin is the largest organ of the body and is divided into three main layers; the 
epidermis, dermis and subcutaneous tissue.1 The epidermis is the outer part of the skin 
and is composed of multi-layered squamous epithelial cells (keratinocytes) and 
specialized dendritic cells (mainly Langerhans cells and melanocytes). In the lower part 
of the epidermis (stratum basale) cells divide and as they mature they proceed gradually 
towards the skin surface and eventually die (Figure 1). The outermost layer of the 
epidermis (stratum corneum) consists of cells without nuclei or organelles. Its structure 
provides an important barrier property of the skin that protects the body from infection, 
dehydration, chemical and mechanical assault. This barrier mainly consists of protein-
enriched cells and of a lipid bilayer. The epidermis is separated from the dermis by a 
basement membrane, the primary function of which is to anchor the epithelium to the 
dermis. The dermis consists of connective tissue and is divided into the superficial 
papillary and the deeper reticular layers. It contains blood vessels, lymph vessels, hair 
follicles, eccrine and apocrine sweat glands, sebaceous glands and nerves. The 
subcutaneous layer is mostly composed of fat and connective tissue.  
                     
Epidermis
Dermis
Stratum corneum
Stratum granulosum
Dermis reticulare
Dermis papillare
Stratum basale
Stratum spinosumŻ
ŻŻ
Ż
Ż
Ż
                     
Figure 1.
Histological picture of normal skin. HES (x200). (Provided by Bofin AM.) 
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Skin damage can induce uncontrolled cell growth and skin cancer.  
 
Basalcellcarcinoma
The three major types of skin cancer are malignant melanoma, squamous cell carcinoma 
(SCC) and basal cell carcinoma (BCC). BCC is the most common cancer in the fair-
skinned population. It accounts for approximately 75% of all non-melanoma skin 
cancers (NMSC) and its incidence is increasing.2 The annual incidence rates vary in 
different parts of the world with higher incidence in locations near the Equator. The rate 
is reported to be from 40 to 200 per 100 000 people per year in Northern Europe to over 
700 per 100 000 people per year in Australia.3,4 A total of 5 163  new BCC cases were 
reported to the Cancer Registry of Norway in  2008, after which time the Registry has 
discontinued registration of BCC in their reports (oral communication with the Cancer 
Registry of Norway). The true Norwegian numbers of new cases is most likely much 
higher, given that the population of Sweden is about twice that of Norway and that more 
than 30 000 BCCs are annually reported to the Swedish Cancer Registry.5 Although the 
incidence of the disease increases with age, BCC is becoming more common in younger 
patients, especially women under 40 years old.6 The life time risk of BCC in the white 
population in the United States is 33-39% for men and 23-28% for women.7  
BCC is a slow growing, locally invasive epithelial tumour that may cause significant 
tissue destruction and patient morbidity. It is therefore important that BCC is diagnosed 
early and managed properly.2,8 Metastasis of BCC occurs only rarely, with reported 
rates varying from 0.0028% to 0.55%, and has been suggested to be associated with 
large tumours (>10 cm), tumours with deep penetration, perineural and blood vessel 
invasion, metatypical tumours, previous radiotherapy and multiple recurrences.4,9 
Recognized patient risk factors are: male gender, red hair, fair skin and blue/green eye 
colour, higher social class, northern European ancestry and inability to tan easily.10 The 
occurrence of consecutive tumours is common.  In three years the risk of a patient with 
BCC to present with another lesion varies from 27 to 44%, reaching 50% in five years. 
With each new tumour the risk increases further.11-13  
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Aetiology
BCC is understood to result from an interaction between environmental exposures and 
genetic factors and may be associated with certain genodermatoses.2,13-15 It is believed 
to derive from the immature, non-keratinizing cells located in the follicular bulges and 
the interfollicular basal layer of the epidermis.2 Cancer is the result of the cumulative 
effect of various types of damage to the cell’s deoxyribonucleic acid (DNA) and 
signalling systems. This can lead to uninhibited proliferation and growth and loss of 
regulatory pathways, such as apoptosis (programmed cell death).16  
Exposure to ultraviolet radiation (UVR), particularly the ultraviolet B spectrum (280-
320 nm), is a key risk factor associated with the genesis of BCC.17 UVR generates 
mutagenic DNA-products, cytotoxic and mutagenic free radicals and causes 
immunosuppression of the skin, harming the local antitumour monitoring activity.13,17-19 
The association between UV exposure and development of BCC appears to be complex 
as the timing, pattern and cumulative exposure to UVR all seem to play a role. Nodular 
BCCs are more associated with chronic exposure, while superficial BCCs are more 
associated with intermittent and intense sun exposure. Recreational sun exposure to 
high doses of UV rays in childhood or youth is a strong risk factor. The greater the 
number of sunburn episodes experienced before the age of 15, the greater the risk of 
tumour development.10,20,21  However, since BCC also may arise on skin not exposed to 
sunlight, factors other than UVR may contribute to BCC development. Among such 
factors are exposures to toxic substances (arsenic and coal tar derivates), foci of 
inflammation (chronic wounds, burn sites), ionizing radiation and conditions that 
weaken the immune system such as treatment with immunosuppressive drugs.22,23  
The oncogenesis of BCC may involve various genetic and molecular pathways as 
well as cellular changes, but is presently considered to depend primarily on the failure 
of tumour suppression.4,18 UVR can damage tumour suppressor genes such as the p53 
gene, which is involved in surveillance of the regulation of cell proliferation and death.  
Mutations in the p53 gene are present in more than 50% of BCCs. However, this gene is 
more closely related to the progression of this tumour than to its origin.19,24 The tumour 
suppressor patched (PTCH) gene, originally identified in Drosophila melanogaster 
(fruit fly), is important for appropriate activation of the hedgehog signalling pathway, 
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implicated in the formation of embryologic structures and in tumour genesis. 
Dysregulation of this pathway is thought to be important in the development of BCC. 
Mutations in the homologue PTCH 1 segment gene located on the q arm of 
chromosome 9 are associated with BCC in almost all cases of Gorlin-Goltz syndrome  
(Gorlin syndrome, nevoid BCC syndrome, basal cell nevus syndrome, multiple BCC 
syndrome), and this association has been vital for the understanding of BCC 
pathogenesis. Loss-of-function mutations of the PTCH gene also appear in 30 to 70% of 
sporadic BCC cases.4,14,18,25 Gorlin-Goltz syndrome is inherited in an autosomal 
dominant manner and its main clinical manifestations include multiple BCCs, multiple 
odontogenic keratocysts of the jaws, palmoplantar pits and skeletal abnormalities.26 
Heritable conditions such as Gorlin-Goltz, Bazex, Rombo and xeroderma pigmentosum 
syndromes predispose to development of BCCs, and should be considered when there 
are multiple BCCs at a young age.4,26,27 Genome sequencing studies have also identified 
mutations in genes involved in pigmentation, DNA repair and immune response, and 
these mutations are more prevalent in patients with BCC than in controls.4,19  Higher 
levels of the apoptosis inhibitory bcl-2 protein have also been found in sporadic BCCs, 
particular in superficial and nodular types of this tumour.2   
 
Clinicalpresentation
BCC can be classified into a number of different types of which the three main 
recognised clinical subtypes are: nodular (noduloulcerative, “rodent ulcer”), superficial 
(multicentric) and morphoeiform/infiltrating (morpheic, mopheaform, sclerosing) 
(Figure 2).2 The majority of lesions develop on sun exposed skin. About 50 to 80% are 
located on the face (30% nose) and neck, 11 to 47% on the trunk and extremities and a 
small number in photoprotected and intertriginous areas.4,20,28  The frequency of the 
clinical types differs among populations. The most common form is the nodular type.  
Both nodular and morphoeiform types predominate on the head. The superficial type is 
the second most common form and most often appears on the trunk.4,20  
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Figure 2. 
Clinical presentations of the most common types of BCC: (a) superficial, (b) nodular 
and (c) morphoeiform. (Provided by Christensen E.) 
 
The superficial type may present as a relatively flat, erythematous plaque, at times 
with a slightly elevated, translucent threadlike border, and is often multifocal. A few 
scales may be present and areas of atrophy and hypopigmentation may be seen. The 
nodular type often appears as an isolated, pearly pink or flesh coloured papule or nodule 
with surrounding telangiectasias. Lesions may have a translucent or slightly 
erythematous rolled border and show occasional bleeding, scaling, crusting or 
ulceration. BCC, mainly superficial and nodular types, may in a few cases be brown-
black pigmented in some or all areas. The morphoeiform/infiltrating type most typically 
presents clinically as an ivory or yellowish irregular shaped, depressed scar with ill-
defined borders. Not all BCCs have a clear-cut clinical appearance, as demonstrated by 
the fact that the clinical diagnosis is not always consistent with the histopathological 
report.29,30  
 
Histologicalpresentation
At present no universally agreed histopathological classification exists for BCC.31  In 
1978 Wade and Ackerman32 described 26 histopathological variants of this tumour. 
Other authors have since suggested a simplified classification that is easier to use in 
both clinical and histopathological practice.33 Identification of the different histological 
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subtypes based on tumour growth pattern, can be done on routine haematoxylin, eosin 
and saffron (HES) stained slides from biopsy specimens. Based on its architectural 
pattern, BCC can be divided into different histological subtypes (Figure 3).  
 
 
Figure 3. 
Histopathological patterns of common subtypes of BCC: (a) superficial (x200),  
(b) nodular (x100) and (c) morphoeiform (x100). (Provided by Bofin AM.) 
 
The most common subtypes include the superficial, nodular, micronodular, 
morphoeiform/infiltrating and metatypical types.2 Histologically, the superficial type 
shows nests of tumour cells that are in continuity with the epidermis. The nodular type 
typically presents with large islands of tumour cells with smooth borders where the 
tumour cells tend to lie in a so-called palisading fashion. The islands of tumour cells are 
often detached from the tumour stroma (stromal retraction). The 
morphoeiform/infiltrating type is characterized by the presence of irregular nests and 
strands of atypical basal cells embedded in a dense fibrous stroma. The extent of 
infiltration may not be readily appreciated on clinical inspection.  It may invade deeply 
into subcutaneous fat and the risk of subclinical spread is higher with tumours of this 
type.34 The micronodular type consists of small nodules and is considered to be more 
aggressive than the nodular type. The metatypical type is a rare, aggressive type of 
tumour with characteristics of both BCC and squamous cell carcinoma. In more than   
40% of cases BCC presents with a mixed histological growth pattern.35  
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One of the main purposes in classifying BCC is to be able to correlate different 
subtypes with biological behaviour, thereby providing the clinician with prognostic 
information useful in the management of these cases.33,36 Nodular and superficial BCC 
are commonly regarded as non-aggressive, whereas morphoeiform/infiltrating, 
micronodular and metatypical types are categorised as aggressive. 
 
Cytologicalpresentation
Skin scrape, imprint and fine needle sampling from BCC may give cellular smears 
comprising cohesive, anastomosing sheets of small epithelial cells or club-like 
formations with a high nuclear-to-cytoplasmic ratio and indistinct cell borders (Figure 
4).
 
 
Figure 4.
Cytological presentations of skin scrape in BCC: (a) sheets of atypical basal cells 
forming club-like structures with smooth peripheral edges and (b) club-shaped fragment 
of tumour tissue with atypical basal cells with peripheral palisading and an area of pink 
stroma adjacent to the tumour cells. (Provided by Bofin AM.) 
 
At the edges the cells often appear to be slightly elongated with focal peripheral 
palisading of the nuclei. There is little variation in nuclear size and shape. However, the 
nuclei are hyperchromatic, round or oval in shape with finely granular chromatin and 
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small nucleoli. Nuclear moulding may be seen. Occasional, pink-staining fragments of 
basement membrane matrix may be observed. Keratinised squamous cells and melanin 
may also be seen. The basaloid cells of BCC have some similarities with cytological 
material from skin adnexal tumours such as trichoepithelioma, trichoblastoma, 
syringoma and metastatic small cell carcinoma.37,38  
 
Diagnosis
BCC should be carefully examined before the choice of treatment is made. Clinical 
diagnosis of BCC is mainly established by means of inspection and palpation of the 
lesion. The proportion of clinically diagnosed BCCs without histological confirmation 
differs between countries and has been shown to be 0.7, 7.1, 17.4 and 24.1%, in Malta, 
the Netherlands, Finland and Scotland, respectively.39 Agreement between the clinical 
and histopathological diagnosis of BCC has been found to be from 64 to 98%.29,30,40,41 It 
has been shown that variation in the sensitivity for clinical diagnosis of BCC depends 
on the experience of the clinician with a rate of 89% for skin cancer doctors versus 79% 
for general practitioners.42 In a prospective study among plastic surgeons, 70% of 
lesions suspicious of BCC were confirmed on histology.43  
Dermoscopy (dermatoscopy, epiluminescence microscopy) may add diagnostic 
information.44,45 It is a non-invasive optical magnification tool widely used in the 
clinical setting. The magnification provided may vary depending on the instrument, and 
the penetration depth reaches approximately the level of the papillary dermis. A 10-fold 
magnification is standard for hand held devices. There are two main types of 
dermoscopes; non-polarised and cross-polarised types. With traditional dermoscopes the 
lens is placed directly on the lesion of interest after application of immersion oil. Cross-
polarised light dermoscopes are small, more flexible and non-touch devices. Multiple 
lesions can be examined quickly without interface fluid application.  With the use of 
dermoscopes pigmented BCC may more easily be distinguished from other pigmented 
skin tumours.46  The most reliable dermoscopic features of BCC are arborizing vessels, 
grey-brown ovoid nests of cells and brown to grey/blue discrete bulbous structures 
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forming leaf-like patterns.47 Dermoscopic sensitivity for BCC diagnosis have been 
shown to rage from 87 to 96% and specificity from 72 to 92%.44  
If a conclusive diagnosis cannot be made based on inspection, palpation and 
dermoscopic examination, histopathological examination of the tumour may be 
required. Currently, histopathological examination of the tumour specimen is 
considered to be the “gold standard”.44 The three most common skin biopsy techniques 
with respect to BCC are: shave, punch and incisional/excisional biopsy.48  An 
incisional/excisional biopsy is often elliptical and performed using a scalpel.  It can 
include the whole lesion (excisional) or part of a lesion or part of the affected area and 
surrounding normal skin (incisional). The biopsy wound is normally sutured and leaves 
a scar. Incisional/excisional biopsy has the advantages of providing a substantial portion 
of the lesion with intact histopathological architecture for further investigation in the 
laboratory. Shave and punch biopsies are widely used for taking minor tissue samples. 
Both techniques are relatively easy to perform, but normally require local anaesthesia 
before use. Shave biopsy is well suited for the investigation of superficial lesions while 
a punch biopsy is preferred of BCCs that are expected to grow deeper into the skin.49 
Biopsy punches are round knives that vary in size and can penetrate into subcutaneous 
tissue. Even small diameter tissue samples are adequate for histological diagnosis.50 
Small diameter punches heal well without suturing. However, both punch and shave 
biopsy frequently leave scars.48  
The sampling procedure for cytological diagnosis is minimally invasive and 
normally induces no scar formation. It is a method only occasionally reported in the  
diagnosis of skin cancer despite its widespread use in the investigation of other types of 
malignancies.51 Cytological characteristics of BCC are readily identified by microscopic 
examination of a cytological smear or imprint if sufficient cell material is obtained. It is 
easy and rapid to perform and requires minimal equipment. No local anaesthesia is 
needed. It is therefore an attractive diagnostic method to be considered, particularly with 
minimally invasive treatment options where cosmetic result is of great importance. 
The three most frequently used methods for sampling of cell material are: fine needle 
aspiration, skin scrape and touch imprint.37 Fine needle aspiration is most often 
employed for taking of samples from skin nodules and deeper lesions.52 Skin scrape and 
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touch imprint are taken from the surface of the lesion after the removal of the keratotic 
surface and/or crusts. In skin scrape cytology the cellular material is scraped from the 
surface of the lesion with a small curette and then smeared onto the glass slide. In touch 
imprint the glass slide is gently pressed against the surface of the lesion and then lifted 
away. The sampling of cell material is even more rapid using touch imprint than skin 
scrape, making this procedure attractive in a busy clinical setting.  
Studies of skin scrape cytology in BCC have been carried out using various staining 
techniques. However, no comparison of diagnostic sensitivity between different stains 
appears to be reported.53 Among several staining techniques available, the Papanicolaou 
(Pap) stain has most frequently been used.53 This stain requires immediate fixation of 
the smear in alcohol and is particularly useful in the visualization of nuclear chromatin 
patterns and to differentiate between keratinizing and non-keratinizing cells. It is also 
well suited to demonstrating the various degrees of squamous epithelial maturation. 
Nuclei stain blue and cytoplasmic staining vary from blue/green in immature cells to 
pink and orange in mature, keratinized cells. The May-Grünwald Giemsa (MGG) stain 
has also been reported in skin scrape cytology of BCC. This stain is performed on air-
dried smears, making it even simpler to use. It is especially helpful in showing the non-
epithelial stromal elements of the cell material which appears as a pink, amorphous 
material. This is often quite difficult to see in Pap-stained smears. Modified MGG stains 
are available for rapid staining.54 
In addition to the above described methods, the range of other tools for diagnosis of 
NMSC, including BCC, is increasing.44 In the past 10-15 years, a number of non-
invasive or minimally-invasive technologies have been developed that also may allow 
the examination of tumours in vivo. Besides the possibility of a diagnosis, they may 
offer the potential to delineate lesion borders and to monitor results after 
treatment.44,45,55,56 The applications of such tools are at present principally limited to 
specialised centres or research facilities. They vary considerably with regard to skin 
penetration depth, resolution and clinical applicability.  
Optical coherence tomography (OCT) provides cross-sectional tomographic images 
of skin by reflection of infrared light that is measured and demodulated in a digital 
form. The layers of the skin as well as adnexal structures and blood vessels can be 
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visualized. OCT may provide information about tumour architecture and morphology, 
but no cellular details are seen. High frequency ultrasound (HFUS) uses pulsed 
ultrasound with frequencies between 20-100 MHz to evaluate skin morphology.  The 
intensity of the echo backscattered from tissue is registered. HFUS imaged skin tumours 
appear echo-poor in comparison to the surrounding tissue. Images are obtained in 
vertical sections and penetration depth and resolution is related to the frequency. The 
advantage of this method is deep penetration, but resolution does not permit 
differentiation of histological subtypes. Confocal microscopy (CM) or confocal laser 
scanning microscopy is an imaging technique used to increase optical resolution by 
elimination of out-of-focus information from the object being studied. Conjugated 
horizontal planes within the tissue are scanned using a low-power laser light source. It 
produces views at a very high resolution comparable to routine histology sections. The 
epidermis and superficial dermis are visualized, but depth of penetration is a limiting 
factor. Reflectance CM is based on the reflectance, scattering and absorption of 
monochromatic light by endogenous chromophores like melanin, haemoglobin and 
other cellular structures, whereas fluorescence CM imaging is based on the visualization 
and interpretation of intra- and intercellular accumulation of endogenous or exogenous 
fluorophores. Another related technique is multiphoton laser scanning microscopy, an 
advanced fluorescence microscopy technique, which could potentially be applied for 
diagnosis of superficial BCC.57  
BCC may also be detected by the use of optical spectroscopy techniques such as 
Raman spectroscopy or by use of pulses of electromagnetic radiation in the frequency 
range of terahertz. In addition, different fluorescence imaging techniques have large 
potential for visual demarcation of tumour borders.44 The British Association of 
Dermatologists considers investigation by computer tomography  or magnetic resonance 
imaging scanning to be indicated in BCCs where bony, orbit or parotid gland 
involvement is suspected or where tumour may involve nerves.58 Computer tomography 
and magnetic resonance studies of SCC and BCC have shown that positive perineural 
spread is inversely correlated with 5-year survival rate.59  
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Differentialdiagnosis
Several tumours of different origin may clinically resemble BCC (Table 1).  
 
Table 1.
Clinical BCC differential diagnosis  
Superficial BCC Nodular BCC Pigmented BCC Morphoeiform BCC 
Actinic keratosis  Dermal nevus  Malignant melanoma  Morphea 
Eczema  Sebaceous hyperplasia Angiokeratoma Lichen sclerosus 
Bowen’s disease Squamous cell carcinoma  Haemangioma Scar 
Psoriasis Dermatofibroma Blue nevus   
Tinea corporis Epidermal inclusion cyst Seborrhoeic keratosis  
 Furuncle   
 Haemangioma   
 Seborrhoeic keratosis    
 Keratoacanthoma   
 Neurofibroma   
 Trichoepthelioma   
 Molluscum contagiosum   
(Provided by Christensen E.) 
 
Actinic keratosis (AK) is considered in Paper I. AK is a very common skin condition 
occurring among the elderly, appearing singly or more often in groups in large areas 
(field cancerization) on chronically sun-exposed skin areas. It represents areas of 
abnormal keratinocyte proliferation and is widely considered to be precancerous as it 
can progress to SCC in about less than 1 in 1 000 cases per year.60 AKs can have a 
diverse clinical appearance from discrete erythematous to scaly thickened, keratotic 
lesions.61 AK may to some extent be confused with superficial BCC. In cases of clinical 
doubt, either a biopsy for histology or a sample for cytology can provide reliable 
diagnosis. 
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Treatmentmodalities
Complete cure is the primary goal of treatment, but the preservation of normal function, 
good cosmesis and patient preference are also factors that have to be considered in the 
choice of treatment.62 There are many different and well accepted treatment modalities 
available in the management of BCC such as surgical excision, radiation therapy, 
curettage and electrodesiccation in addition to cryotherapy, all yielding favourable 
outcomes.63-66 Surgical excision and radiation therapy appear to be most effective with 
Mohs micrographic surgery (MMS) showing the lowest failure rates.3 
 In addition, successful uses of different types of lasers in the treatment of BCC have 
been described.67-69 Oral vismodegib is a hedgehog signaling pathway targeting agent 
recently approved for treatment of advanced BCC. It has an encouraging anti-tumour 
activity with response rates for locally advanced or metastatic BCC shown in a recent 
open-label study to be 43 and 30%, respectively. The response in patients with 
metastatic tumours, however, was partial and serious adverse events were reported in 
25% of study patients.70   
The development of more effective, minimally invasive topical therapies with tissue-
sparing properties has increased the number of available options for treatment of BCC.71 
Topical photodynamic therapy (PDT) and imiquimod 5% cream are two such therapies 
having become established treatments for selected BCCs. Topical PDT is described in 
more detail in subsequent chapters. Imiquimod is a synthetic immune response modifier 
acting by stimulating innate and cell-mediated immune responses. Favorable tumour 
clearance rates in superficial BCC were found after topical use of imiquimod cream 
formulation five times per week for six to twelve weeks. Various degrees of local skin 
irritation are expected.72,73  
Topical 5-fluoracil 5% cream and perilesional or intralesional administration with 
interferon (interferon alfa-2a/interferon alfa-2b) are two treatment options that are more 
rarely used although they are both found to be effective, largely in the treatment of 
selected small, superficial BCC.71,72 Among investigational agents for topical treatment 
of BCC are tazarotene, cidofovir, solasodine glycoalkaloids and ingenol mebutate.74-77  
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HighandlowͲrisk
One of the main concerns with BCC is the possible risk of local recurrence after 
treatment. With early diagnosis and appropriate therapy, the prognosis is relatively 
good.  However, some patients have lesions resistant to treatment. Based on certain 
characteristics, BCC may be divided into high or low-risk types.58,64,78,79 The highest 
recurrence rates and morbidity are associated with morphoeiform/infiltrative BCC, in 
addition to large size (about >2 cm, but varying depending on the localization), long 
duration, mid-face location, recurrent lesions (failures of previous treatment) and 
perineural invasion. Low-risk tumours are small, well defined, primary, situated at a 
low-risk location and with a non-aggressive histopathology. MMS and excisional 
surgery and to some extent radiation therapy are generally used on high-risk s, while 
less invasive techniques are usually reserved for treatment of low-risk types.58 Not all 
patients qualify for surgery, and excision surgery can in certain anatomic areas be 
challenging and result in cosmetic disfigurement or complications like scar formation 
and functional impairment. Topical PDT, with beneficial cosmesis, may in such cases 
be an attractive treatment option.  
  
Topicalphotodynamictherapy
ResearchinNorway
Extensive PDT research has been carried out at the Norwegian Radium Hospital, Oslo 
University Hospital.80,81 Professor of Biophysics J. Moan recognized the importance of 
singlet oxygen in PDT in the 1970s. In the late 1990s Q. Peng et al 82 found evidence of 
porphyrin production after intraperitoneal injection of 5-aminolaevulinic acid (ALA) 
into tumours in mice. The Norwegian based pharmaceutical company Photocure ASA, 
was started in1993 to commercialise and carry out further development of 
photodynamic technologies. Methyl aminolaevulinate (MAL), a lipophilic derivate of 
ALA, shown to be more selectively taken up in BCC than ALA, was developed.83 Dr. 
T. Warloe started clinical studies using topical PDT in the treatment of BCC and 
showed that supportive tissue penetrator enhancers and curettage improved the 
outcome, particularly in nodular BCC (1995).84 Further studies on ALA- and MAL-
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PDT in BCC was carried out by dr. A.M. Solér (2002),  who demonstrated high 
complete response rates even after treatment of nodular tumours.85 From September 
1997, the Department of Dermatology, St. Olavs Hospital, Trondheim University 
Hospital, started treating NMSC with topical PDT on a regular basis. Treatment 
procedures were carried out in accordance with the then current practice at the 
Norwegian Radium Hospital, Oslo University Hospital. 
 
Mechanismofaction
Topical PDT is based on tissue destruction caused by the interaction of light with a 
photosensitizer with relatively selective uptake by malignant cells and oxygen to 
produce reactive oxygen species (ROS), such as cytotoxic singlet oxygen (Figure 5).83 
PDT effect is not only confined to the direct, targeted destruction of cells at the 
treatment site.  The release of cell fragments, cytokines and inflammatory mediators that 
activates the host’s innate and adaptive immune system, may lead to further cell 
destruction.86                                 
reactive
oxygen
species
(ROS)
photosensitizer
O2light
 
 
Figure 5. 
Mechanism of action of PDT. (Provided by Mørk C and Christensen E.) 
 24
Photosensitizers 
Photosensitizers are substances that absorb light energy and transform this energy into 
chemical reactions. Several dyes are applicable as photosensitizers in PDT, but only a 
few are commonly used in clinical trials and standard PDT treatment of BCC.87,88 
Systemic photosensitisation is avoided in topical-PDT.83,88 The most frequent, topically 
applied substances used for treatment of BCC are ALA and MAL. These substances are 
not photosensitive themselves but enter the haem biosynthetic pathway. Haem is 
synthesised in mammalian cells. After cellular uptake, MAL is rapidly demethylated to 
ALA. ALA is a haem precursor, and is metabolized to photosensitive porphyrins, 
particularly protoporphyrin IX (PpIX). When irradiated and in the presence of oxygen, 
PpIX is excited and produces ROS, mostly cytotoxic singlet oxygen, leading to cell 
death by necrosis and apoptosis, depending on the amount of ROS formed (Figure 5).89 
Cell necrosis is a pathological process generally associated with severe cellular trauma, 
which leads to cell death. Apoptosis is programmed cell death characterized by cell 
membrane changes, nuclear shrinkage and DNA fragmentation.  The genotoxic and 
mutagenic potential of topical PDT is considered to be insignificant. PpIX is mainly 
formed in the inner mitochondrial membrane. The action radius of singlet oxygen is 
very short, thus the induced photochemical reaction hardly affects directly on the cell 
nucleus.90  
The first of several steps in haem synthesis comprises the condensation of glycine 
and succinyl-CoA to ALA. Formation of porphobilinogen and subsequent steps in the 
synthesis lead to the build-up of PpIX. The final step to form haem is the incorporation 
of iron catalyzed by ferrochelatase into PpIX (Figure 6).83 The haem biosynthetic 
pathway is normally regulated under close feedback control. Haem inhibits the 
formation of ALA.  When ALA is given in excess, ALA bypasses the cellular feedback 
control system leading to the accumulation of photosensitive porphyrins in the 
mitochondria, lysosomes and membranes of the cell.  The PpIX synthesis and 
accumulation is higher in BCC compared to normal tissue.  This is due to factors such 
as increased ALA and MAL penetration through the defect skin barrier in tumours and 
alteration of cellular enzyme activity in neoplastic tissue. Increased porphobilinogen-
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deaminase and decreased ferrochelatase enzyme activities contribute to higher 
accumulation of PpIX.  
 
  
 
 
Figure 6. 
Simplified presentation of the haem biosynthetic pathway. (Provided by Christensen E.) 
 
 
ALA is a hydrophilic molecule, which limits its ability to penetrate through cellular 
membranes. MAL, an ester of ALA, is more lipophilic and may have higher tumour 
selectivity than ALA.91,92 However, no difference between transdermal penetration of 
MAL and ALA has been shown in BCCs 93, and similar effectiveness of MAL- and 
ALA-PDT has been found after treatment of this type of skin cancer.94  
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Lightsources
Broadband and narrow band light sources such as halogen lamps and light emitting 
diode (LED) lamps, lasers or daylight, may be used for topical PDT. Halogen lamps are 
cheap and have been widely used, but overheating of the skin may be a problem unless 
the lamp is equipped with optical filters. The LEDs are simple to use and give off less 
heat. The exposure time to both halogen lamps and LEDs is usually about 10 minutes.88 
Fractioning of light exposure may improve treatment response by promotion of the 
photodynamic reaction.95 Lasers provide the exact selection of wavelengths that match 
the absorption peaks of the photosensitizer and allow shorter treatment time. Daylight-
PDT is currently used for treatment of AK and is also considered in the management of 
BCC. It is more time-consuming than using traditional light sources, but has the 
advantage of an almost total elimination of treatment related pain sometimes 
experienced with the other light sources and may improve the logistical challenges 
associated with traditional PDT.96   
The light source used with PDT must emit wavelengths in the absorption spectrum of 
the photosensitizer. PpIX has a high absorption peak at about 405 nm (blue light) and 
several smaller bands at approximately between 510 and 630 nm (red light). Most light 
sources take advantage of the 630 nm absorption peak of PpIX to optimize tissue 
penetration.83,88 Long wavelengths penetrate more deeply into tissue than short 
wavelengths, and the degree of photoactivation is dependent on the amount of light that 
reaches and is absorbed by the photosentiziser. For thin, epithelial lesions blue light 
may penetrate sufficiently deep into the skin. In the treatment of thicker BCC, however, 
a red light source is preferred as it allows a deeper penetration of light into tissue. 
However, due to light scatter in skin, therapeutic red light extends only to a depth 
between 1 to 3 mm.97  The contribution of emission wavelengths beyond 630 nm that 
may activate porphyrin photoproducts is not known.98 
Under exposure to blue light the PpIX enriched tumour can be visualized by 
fluorescence.99 Fluorescence is the property of a substance to absorb light of a short 
wavelength and emit light of a longer wavelength. PDT fluorescence can be used in 
photodetection of malignancies and to delineate poorly defined lesions.100  
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Advantagesanddisadvantages
Topical PDT is a relatively selective, tissue sparing, non-invasive treatment for BCC. 
This contributes to a favourable post-treatment cosmetic outcome.87 It is particularly 
suited for treatment in patients with multiple co-morbidities, high risk of postsurgical 
scarring with or without functional impairment, multiple and/or large lesions, in cases 
where more invasive treatments are contraindicated and for lesions located to sensitive 
skin areas where cosmetic outcome is of major concern. Several lesions may be treated 
simultaneously and the same lesion can be treated repeatedly with success if required. 
Topical PDT may also be used with success in combination with other treatment 
modalities.101,102  As topical PDT usually is performed in a medical setting, patient 
compliance to treatment is high. 
Frequent local skin reactions to the treatment site are erythema and oedema. Some 
patients experience treatment-related pain that usually ends shortly after therapy. The 
mechanism of this pain is not fully understood. It may be associated with stimulation of 
nerves through receptors located at the endings of myelinated A delta and unmyelinated 
C fibres, and with factors such as local hyperthermia and inflammation of the treatment 
area. There are a number of actions that can control mild to moderate pain such as the 
use of cold water and/or cooling fans, whereas infiltration anaesthesia or nerve block 
can be used for management of severe pain.103,104 Allergic reactions to ALA or MAL 
are rare.105 A challenge with topical PDT is the treatment of thicker tumours.106-108 The 
method has limited skin-penetrating abilities with ALA and MAL shown to penetrate 
BCCs efficiently only to a depth of approximately 2 mm 91,93,109, and there is also a 
limitation of tissue penetration by red light. Topical PDT is not considered to be the 
treatment of choice for the aggressive and pigmented BCC subtypes.83,110  Aggressive 
BCC subtypes tend to show a local invasive behaviour and are surrounded by abundant 
collagen fibres which may reduce penetration of topical ALA and MAL.79  In 
pigmented BCC, optimal light penetration may be inhibited by melanin molecules.110 
PDT performed as mono-therapy does not provide tissue specimens for 
histopathological examination and confirmation of the clinical diagnosis before 
treatment.54,62,105 The standard procedure of topical PDT can be regarded as both time- 
and resource-consuming. The application time for MAL is routinely 3 hours, which is 
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the time needed for advantageous porphyrin synthesis and distribution in the tumour 
before illumination.111 In addition, topical MAL-PDT for BCC is currently approved for 
two treatment sessions one week apart.87,112  
 
Earlyclinicalexperience
Topical PDT has increasingly been used in the treatment of BCC since the pioneer work 
published by Kennedy in 1990.113 Early clinical PDT studies demonstrated promising 
treatment outcome, superior cosmesis and few side effects.106,113 In 12 ALA-PDT 
studies carried out from 1990 to 1995 reviewed by Peng et al.83, the average clearance 
rate was 87% in superficial BCC, but with lower response rates in nodular tumours. 
Morphoeic and pigmented lesions responded inadequately to topical PDT. There was no 
standardised treatment protocol. Most early studies used 20% ALA in an oil-water 
emulsion, application time varied from 3 to 8 hours and different light sources were 
used.83,114 Only one treatment session was usually performed, although some studies 
suggested improved outcome by repeat treatment sessions.106,115,116 Histopathological 
confirmation of BCC clearance after treatment was rarely obtained. In an early study by 
Calzavara-Pinton et al.106, treatment areas were surgically removed one month after 
ALA-PDT.  Remnants of BCC, particularly nodular tumours, were found in several of 
the areas in clinically complete remission. Early studies also demonstrated that 
clearance rates depend on follow-up time; 75-100% after 1-3 months decreasing to 50-
92% after 7-36 months.83,106,117,118  
Recurrence rates for BCC after traditional treatments have been shown to depend on 
the length of follow-up, and recurrences have also been shown to occur many years 
after therapy.63,64 The slow growth rate of BCC is claimed to be a factor that makes 
even 5-year follow-up after treatment inadequate.63 Prolonged clinical and histological 
follow-up data on topical PDT in BCC is therefore required for evaluation of its long-
term effect, and needed for comparison with standard therapeutic procedures.  
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Tumourthickness
A challenge in the treatment of nodular BCC is to ensure penetration of ALA and MAL 
into the full thickness of the tumour.  The inferior topical PDT response of nodular 
compared to superficial BCCs led Warloe et al.119,120  to attempt new strategies to 
optimize treatment effect, including the use of tissue penetration enhancers such as 
dimethylsulfoxide (DMSO) and pre-PDT curettage.  
DMSO is a chemical solvent with a wide range of physical and chemical properties. 
It can disrupt the skin barrier through extraction of skin lipids and denaturation of the 
stratum corneum proteins, thereby permitting increased drug uptake. In addition, DMSO 
can carry other drugs with it across membranes, and has been shown to increase the 
permeation of 5-ALA through hairless mouse skin and to initiate haem biosynthesis and 
endogenous porphyrin production.121-123 Using DMSO supportive topical ALA-PDT in 
combination with a porphyrin production inducer (ethylenediaminetetraacetic acid, 
EDTA), Warloe et al.119 achieved an improved clinical result for both superficial and 
nodular BCCs. Tumour clearance rates increased from 67 to 90% for tumours less than 
2 mm thick, and from 34 to 50% for thicker BCC. 
Curettage is a physical method aimed to remove superficial, hard keratotic tissue and 
the upper part of the epidermis from the lesion surface before treatment. Thicker BCCs 
may additionally require intratumoural curettage (debulking), where loose-meshed 
tissue is removed, reducing the thickness of tumour.124 Curettage prior to topical PDT 
may improve ALA and MAL tumour penetration.105,125 Thissen et al.126 reported 92% 
histological clearance in 24 nodular BCCs using PDT with prior debulking. Warloe et 
al.120 demonstrated that by performing a simple curettage prior to ALA-based topical 
PDT the complete response rate for thick (> 2 mm) BCCs increased from about 50 to 
89%. 
According to the international consensus guideline, PDT is recommended as a 
treatment option for superficial and thin nodular BCCs (thickness < 2 mm).87,112  Some 
investigators, however, accept 2-3 mm thick BCCs for PDT when combined with prior 
curettage (debulking).87,110 To achieve a good result it is important to identify those 
tumours most likely to respond to treatment. Careful selection of BCC, with thickness 
up to about 2 mm, for treatment may thus increase the success rate of topical PDT in 
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BCC. Although BCC characteristics in daily practice may be assessed by clinical 
examination, the histological examination of biopsy specimens is perceived to give a 
more accurate measurement of tumour thickness.62  Such information can prove 
important in the evaluation and selection of BCCs most suited for PDT. The taking of a 
pre-treatment biopsy is therefore encouraged.62,105,127 A limitation of punch biopsy, 
however, is that it will only offer information from a small, selected area compared to 
an excision specimen which allows a more extensive examination of the tumour.  
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AIMS OF THESIS
The general aim of this thesis was to study selected diagnostic methods for BCC in 
relation to topical PDT and long-term treatment results. This was done by investigating 
various aspects of cytological diagnosis in BCC and whether punch biopsy provides 
sufficient information about BCC tumour thickness for adequate selection of lesions 
suitable for treatment with topical PDT. The long-term treatment results were obtained 
by regular and careful prospective clinical and histological follow-up of the treatment 
areas in patients having received curettage and topical PDT for BCC. 
 
 Specifically, we sought to: 
x Evaluate the diagnostic performance of skin scrape and touch imprint cytology 
in BCC. 
x Compare two different cytological staining methods in the diagnosis of BCC. 
x Investigate the agreement between tumour thickness measurements in paired 
punch biopsy and excision specimens from individual BCCs.  
x Investigate 6-year treatment efficacy and cosmetic outcome in treated areas 
clinically considered to be in complete remission at 3 months after curettage and 
one or two sessions of topical DMSO-ALA-PDT in BCC. 
x Describe BCC tumour recurrence over time after treatment by curettage and 
topical DMSO-ALA-PDT, and explore clinical and histopathological factors 
associated with treatment failure. 
x Investigate 10-year treatment efficacy and cosmetic outcome of primary and 
recurrent BCC after curettage and one or two sessions of topical DMSO-ALA-
PDT.  
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MATERIAL AND METHODS 
All patients were referred to the outpatient clinic at the Department of Dermatology, St. 
Olavs Hospital, Trondheim University Hospital. Different cohorts of patients were 
studied in paper I, II and III/IV.   BCC and AK lesions were histopathologically 
confirmed. In Papers I, III and IV the skin lesions were treated with topical PDT. In 
Paper II, the selected method of treatment was surgery. Specific inclusion and exclusion 
criteria were defined (See enclosed publications for details). 
In Paper I, we compared cytodiagnostic skin scrape and touch imprint results with 
the histological diagnosis in 50 BCC and 28 AK lesions from 41 and 25 patients, 
respectively. All cytological specimens were examined in a random and blinded fashion 
by two pathologists. The histopathological diagnosis was considered to be the “gold 
standard”. 
In Paper II, we compared tumour thickness measurements of individual tumours in 
punch biopsy and the corresponding excision specimens from 48 BCCs in 43 patients. 
In Paper III, we performed a long-term (6 years) follow-up of 60 BCCs in 44 patients 
treated with one or two sessions of topical DMSO-ALA-PDT following curettage which 
clinically appeared to be in complete remission 3 months after therapy (Figure 7). At 
the beginning of the study, in September 1997, all lesions received two treatment 
sessions one to two weeks apart. From February/March 1998, only one session was 
given. Evaluation of the treated areas was done at regular intervals; 3, 6, 12, 24, and 72 
months after treatment. The post-treatment follow-up period was initially intended to be 
one year, and was thereafter gradually prolonged. 
In Paper IV, we followed the same cohort as described in Paper III, up to 10 years 
after treatment (Figure 7).  
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
 
n = number of patients 
l = number of lesions 
 
Figure 7. 
Flow chart with number of patients and lesions in Paper III and Paper IV. (Provided by 
Christensen E.) 
 
Procedures
In paper I, a curette was used to gently scrape the surface of a lesion. Then the cell 
material was deposited on a glass slide and spread directly with a second slide. From an 
individual lesion, the first skin scrape smear was stained with Pap and the second was  
stained with MGG. A microscope slide was then firmly pressed against the lesion 
surface to make an imprint. The imprints were stained with MGG (Figure 8).  
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Disposable biopsy punches of 2, 3 or 4 mm in diameter were used to obtained tissue 
specimens for histopathological investigation (Papers I-IV). Biopsy tissue was routinely 
fixed in 4% formaldehyde and further processed before embedding in paraffin wax. 
Sections were cut at 4μm and stained with HES and examined under a microscope. 
In Paper II, a punch biopsy and an elliptical surgical excision were used to provide 
tissue for histopathological investigation. After fixation in 4% formaldehyde the 
excision biopsies were cut into several slices before processing following the same 
procedure as for punch biopsies. 
 
 
Figure 8.
Sampling and staining methods for cytological investigation of BCC and AK and 
numbers of non-evaluable smears. (Provided by Christensen E.)  
 
The punch biopsy for investigation of tumour thickness was taken from the part of the 
tumour clinically considered to be thickest. If the tumour on clinical inspection and 
palpation appeared of homogenous thickness the biopsy was taken from the central area. 
After obtaining the punch biopsy, an elliptical excision of the whole tumour was 
performed (Figure 9).  
In Papers III and IV, curettage of BCC and the surrounding skin was performed on 
all lesions. Additional careful intratumoral curettage (debulking) was included for those 
cases in need of tumour volume reduction.  
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Figure 9.
The sequence of paired punch and excisional biopsies: (a) noduloulcerative BCC, (b) 3 
mm punch biopsy, (c) punch biopsy specimen and (d) elliptical excision. (Provided by 
Christensen E.) 
 
Drugformulationsandlightsource
Three types of drug formulations were used. In Papers III and IV, gauze soaked in 
DMSO 99% was applied on lesions located on trunk and extremities for 5 minutes 
before use of ALA. An emulsion of ALA 20% in Unguentum Merck was then applied 
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for approximately 3 hours before further treatment with light. On lesions located on the 
face and hairy scalp, DMSO 4% was added to the ALA-containing emulsion. A 
broadband lamp developed at the Norwegian Radium Hospital with an emission 
spectrum of 550-700 nm and light intensity at the skin surface of about 150 to 230 
mW/cm2 was used. 
 
Lesion evaluation 
Histological and cytological evaluations of BCC and AK were made in Paper I. In 
Papers II-IV, clinical and histological evaluations of BCC were used. Clinical 
evaluation of BCC and of treatment sites was performed through inspection and 
palpation (Papers II-IV). Lesion size was clinically estimated as the mean value of the 
greatest length and width. The H-zone was defined as the area of the face and ears 
corresponding to the area marked grey on a figure sketch (Paper III) (Figure 10).  
 
 
                                  
                                                  
 
Figure 10.
Anatomical depiction of the “H-zone” marked as a grey area. (Provided by Christensen 
E.)  
 
Cosmetic outcome was assessed at the follow-up visits by the investigator and 
recorded on a 4-point scale as excellent, good, fair or poor (Papers III and IV).  The 
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patients evaluated the cosmetic outcome at the 6-, 12-, 24- and 36-month visits using 
the same assessment scale.  
A punch biopsy for histopathological examination was taken at follow-up from all 
treatment areas clinically suspicious of treatment failure. In addition, treated areas 
clinically considered to be in complete response were biopsied for histological 
investigation at the 12- and 36-month follow-ups (Papers III and IV). Based on 
histopathological investigations of biopsy specimens, BCCs were subtyped by different 
classifications methods. In papers I, II and IV, the classifications were based on 
histopathological growth pattern of tumours.33,128 In Paper III, BCC tumours were 
subclassified as either superficial or nodular type according to whether growth extended 
to or deeper than the papillary dermis.129 Tumour thickness was measured from below 
the stratum corneum to the base of the deepest tumour nest to the nearest 0.1 mm (Paper 
II).  
The cytological features of BCC were based on the presence of tight groups of 
atypical, uniform, small cells, as described in more detail in the introduction part of the 
thesis. The features of AK were based on findings of individual and groups of dysplastic 
keratinocytes often with ragged edges. Intercellular bridges could be seen. The cells 
showed a polyhedral or spindle-shaped configuration and the nuclear-to-cytoplasmic 
ratio was moderate to high. The results of the cytological evaluations were grouped into 
four categories: BCC, AK, non-BCC/non-AK and non-evaluable. 
 
Statisticalmethods
Continuous variables were reported as mean, standard deviation and range.  Categorical 
variables were presented as numbers and/or percentages. Normal distribution was 
assumed when using parametric tests. In Paper II, a paired-sample t-test was used to 
compare the mean of two variables. Agreement between punch biopsy and excision 
specimen tumour thickness measurements was analysed using a difference-versus-mean 
(“Bland-Altman”) plot.130  The 95% prediction limits for excision tumour thickness 
given punch biopsy measurements were obtained by use of a regression approach that 
takes an increasing standard deviation into account.131 In this study a one-sided 
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prediction limit was considered most informative with respect to clinical interpretation. 
Chi-square test of association was used in the analyses of association between treatment 
complete response and treatment failure (categorical variables) (Paper IV) and 
McNemar’s test was used for testing an association between matched pairs (Paper 1). 
The cytodiagnostic performance was expressed as point estimates of sensitivity and 
specificity with 95% confidence intervals using the binominal distribution (Paper I). 
Estimation of probability of treatment failure was conducted using time to event 
(survival) analyses that account for censored observations and Kaplan-Meier plots 
(Paper III and IV). Univariate analyses of different factors were done using the log rank 
test. A Cox model was used to explore the relationship between BCC recurrence and 
possible explanatory variables. This included patient gender, age, immunological status 
and lesion site, size, thickness, subtype, primary or recurrent, in addition to treatment 
related factors as number of treatment sessions and light dose. In Paper IV, the analysis 
was adjusted for clustering of lesion among patients. 
The statistical software R, version 2.5.0 and 2.11.1 and the software SPSS version 15 
were used for statistical analyses. P value less than 0.05 was considered statistically 
significant. 
 
Supplementarystatisticalanalyses
In Paper III, analyses investigating the relationship between BCC recurrence after 
treatment and possible explanatory variables were repeated using a robust variance 
estimator that takes clustering of lesions among patients into account. (The outcome is 
presented under section: Results). 
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ETHICS
The regional committee for medical research ethics approved all the studies.  
The cytological investigation was considered by the committee to be a quality 
assurance study (Paper I). The cell material provided for cytology was obtained as part 
of the pre-treatment PDT procedure. 
The extension of the follow-up period after topical PDT of BCC may have been a 
burden on patients.  However, prolonged follow-up after treatment of this type of skin 
cancer can be advantageous as patients with BCC are at higher risk of developing new 
lesions within a few years. At follow-up, new lesions may be diagnosed and treated at 
an earlier stage than otherwise would have been the case (Papers III and IV).  
Patients who at any time during follow-up were excluded from further study, due to 
clinical and/or histological BCC recurrence or who wished to withdraw from the study, 
were offered additional treatment options at the discretion of the investigator (Papers III 
and IV).
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RESULTS
 
SynopsisofPaperI
Objective: 
To evaluate the diagnostic performance of skin scrape and touch imprint cytology in 
BCC and to compare diagnostic results using two different staining techniques. 
Material and methods:  
Two skin scrape and one touch imprint were taken from each lesion in 50 BCC and 28 
AK lesions. Scrape smears were stained with Pap or MGG stain and imprints were 
stained with MGG. Cytodiagnostic results were compared to the histopathological 
report which was considered the “gold standard”. 
Results: 
x The sensitivity and specificity for skin scrape cytodiagnosis using Pap stain in 
BCC were both 96%.  
x The sensitivity and specificity for skin scrape cytodiagnosis using MGG stain in 
BCC were 94% and 96%, respectively.  
x Skin scrape diagnosis differentiated BCC well from AK. 
x Touch imprint sampling procedure returned non-evaluable material in 32% and 
cytological diagnosis agreed with histopathology in 62% (31 of 50) of samples 
from BCC.    
Conclusion:  
Skin scrape cytology with either Pap or MGG stain, is a useful method and performs 
well for the diagnosis of BCC. Touch imprint cytology was not found useful as a 
routine diagnostic method. 
 
SynopsisofPaperII
Objective: 
To evaluate information from punch biopsies of BCC with regard to tumour thickness. 
Material and methods: 
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From individual tumours, thickness measurements in punch biopsy and the 
corresponding excision specimens of 48 BCCs from 43 patients were investigated. 
 
Results:  
x Tumour thickness was measured to be 0.14 mm greater in excision specimens 
than punch biopsies when comparing the mean (average) measurement of the 
two groups. 
x From individual BCCs, corresponding thickness measurements by the two 
methods showed increasing discrepancy between measurements with increasing 
tumour thickness (Figure 11).  
 
 
 
 
 
Figure 11.
Illustration of the 95% upper prediction limits for excision tumour thickness given the 
punch biopsy thickness measurements by use of a regression model. Two examples are 
shown: a) in tumours with punch biopsy thickness of 1 mm, the excision specimen 
thickness would with 95% probability be less than 2 mm and b) with punch biopsy 
thickness of 2 mm, the excision specimen thickness would be less than 3.5 mm. 
(Provided by Skogvoll E and Christensen E.) 
The line formed by the transition 
between shaded and white area is the 
line of equality. The unbroken line 
shows the mean difference between 
measurements by the two methods. 
The broken line is the upper 95% 
prediction line. 
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Conclusion: 
The prediction of “true” tumour thickness from a single punch biopsy of individual 
BCCs may be uncertain, and prove insufficient for deciding whether or not the tumour 
falls within the current recommended limit, of approximately 2 mm thickness, for 
topical PDT.  
 
SynopsisofPaperIII
Objective: 
To evaluate clinical, histopathological and cosmetic treatment outcome in BCC at 
regular intervals, up to 6 years after curettage and topical PDT, and to evaluate 
associations between treatment response and patient and lesion characteristics. 
Material and methods: 
A total of 44 patients with together 60 histologically verified BCCs were studied after 
treatment with curettage and one or two sessions of DMSO supportive topical ALA-
PDT. Treatment areas in clinical complete response 3 months after treatment were 
followed regularly for 6 years with clinical inspection, histological investigation of 
biopsy samples and cosmetic evaluation. Data from deceased patients were not included 
in the long-term results. Histologically verified BCC recurrences were consecutively 
excluded from the study.  
Results:  
x At 3 months, complete treatment response was observed in 92% (55 of 60) of 
the treatment areas.  
x At 72 months, complete treatment response was observed in 81% (43 of 53) of 
the treatment areas; 68% after one treatment session and 91% after two sessions. 
x Recurrence was noted in 2, 4, 2 and 2 tumours at 6, 12, 24 and 36 months 
follow-up, respectively. 
x Clinical assessment of treatment areas identified 9 of 10 BCC recurrences.  
x The investigator assessed cosmetic outcome was rated as excellent or good in 
91, 97, 97 and 100% at the 12-, 24-, 36- and 72-month visit, respectively. 
x The patient assessed cosmetic outcome was rated as excellent or good in 100% 
at the 24-, 36-and 72-month visits.    
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x Male gender and H-zone location were each associated with recurrence of 
tumour. 
Conclusion: 
Topical curettage and DMSO-ALA-PDT has a favourable long-term outcome in the 
treatment of BCC. Clinical assessment of the treatment areas appears to be sufficient in 
long-term follow-up. 
 
SynopsisofPaperIV
Objective: 
To evaluate 10-year efficacy of curettage and topical PDT in primary and recurrent 
BCC, and to evaluate clinical and histological tumour characteristics that may be 
associated with treatment failure. 
Material and methods: 
The same cohort as described in Paper III, but also including those patients with lesions 
showing  3-month partial response to treatment, were followed up to 10-years after 
curettage and one or two sessions of DMSO-ALA-PDT. Results were reported as 
sustained lesion complete response rate using a time to event analysis, histologically 
confirmed treatment failure and assessment of cosmetic outcome. 
Results:  
x At 10 years, the overall lesion complete response rate was 75%; 60% after one 
treatment session and 87% after two sessions.  
x Lesion complete response rate for primary BCC was 78%; 63% after one 
treatment session and 90% after two sessions. 
x Overall treatment failure was found in 25% (15 of 60) of treated BCC, and all 
were identified within 3 years of treatment.  
x At 10 years, the cosmetic outcome was rated by the investigator as good or 
excellent in 100% of cases.  
x Male gender, recurrent BCC and one treatment session were each associated 
with treatment failure.  
x The only lesion larger than 2 cm in the study relapsed. 
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Conclusion: 
Two sessions of topical DMSO-ALA-PDT with curettage provide high and sustained 
efficacy with favourable cosmetic outcome in the treatment of small, primary BCC. All 
treatment failures appeared within three years after treatment.  
 
Supplementaryresults
By use of a statistical model that takes clustering of lesions into account, male gender  
(p = 0.008) and H-zone (p = 0.028) were found to be associated with tumour recurrence, 
thus leaving the originally reported results unchanged (Paper III).  
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DISCUSSION 
Methods
Paper I reports results from a study comparing different cytological diagnostic methods 
using histology as the reference. In Paper II, the agreement between two methods of 
assessing tumour thickness measurement is investigated. In Papers III and IV, the long-
term outcomes after use of curettage and topical PDT for BCC are reported in a 
prospective cohort study. 
Dermatologists at the out-patient clinic selected lesions (patients) for the various 
treatment modalities. This may have resulted in bias, as treatment was not randomly 
assigned. Thus some patients and certain tumours were less likely to be represented in 
the studies. For example, the overall distribution of BCC shows a predominance of the 
nodular type, which most often appears on the head.20 In Paper II, most of the BCCs 
were of the superficial type and located to the trunk. We suspect that a number of 
patients with nodular facial tumours were primarily referred to the Department of 
Plastic Surgery, where advanced facial surgical procedures are performed at St. Olavs 
Hospital, Trondheim University Hospital. This may have led to a de-selection of 
nodular BCCs for PDT, which further may have affected study results, because nodular 
tumours are presumably thicker than superficial BCCs. If a greater number of nodular 
tumours had been included, the disparity between the two methods of measuring BCC 
thickness might have been greater than shown in the study. 
The sample size in Papers III and IV was limited to the number of patients who 
received topical PDT within one year and met study inclusion criteria while avoiding 
those of exclusion. Fifty-three patients with a total of 72 lesions were treated with 
curettage and topical PDT at the out-patient clinic from September 1997 to September 
1998. A number of these patients and/or lesions were excluded from study follow-up 
due to various protocol violations; one had a lesion surgically removed, but received 
PDT most likely to prevent recurrence; one had a pigmented BCC with a thickness of 
more than 4 mm; one had a tumour that on histology showed a trichoepithelioma; one 
had a BCC diagnosed from a large leg ulcer which required many consecutive PDT 
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sessions and one patient was not suited for undergoing the prolonged treatment 
procedure as required. The remaining were excluded from follow-up because the lesions 
were not biopsied before treatment, thus no histologically verified diagnosis was 
available. Even so, the limited exclusion criteria in Papers III and IV allowed a diversity 
of patients and BCCs to be represented in the cohort, including recurrent lesions and 
lesions in immunocompromised patients that other studies may have excluded. 
However, the numbers of patients and lesions in the cohort is relatively small. This may 
cause low statistical power and in particular limits the potential for subgroup analyses. 
The main outcomes in Paper IV were given as point estimates with 95% confidence 
intervals (CI). A CI is a calculated interval in which the “true” value is contained with a 
defined degree of confidence, normally 95%. It thus quantifies the uncertainty of an 
estimate.132 If the study is repeated many times in the same population, these Cls would 
contain the underlying “true” value in 95% of the time (given 95% confidence). The 
width of a CI is a function of the standard deviation of the sampling distribution 
(standard error) and of the chosen level of significance. The sample size affects the 
standard error. Therefore, by including more BCC lesions, the width of the 95% CI 
around the point estimates of lesion complete response rate could have been narrowed, 
hence, increased the precision of these estimates. 
In Paper I, the CIs of the point estimates for BCC skin scrape cytodiagnostic results 
by both Pap and MGG staining techniques were fairly narrow, indicating that the 
sample size was statistically adequate. The diagnostic ability of cytology was compared 
to histopathology, which was considered the “gold standard”, and reported as the 
sensitivity and specificity. A perfect diagnostic test gives 100% sensitivity and 100% 
specificity. In Paper I, the sensitivity represents the percentage of histologically verified 
BCCs that were correctly identified by cytology. The specificity identifies the 
percentage of negatives that were correctly identified as non-BCC.133 By including 
histologically verified non-BCCs (AKs), the specificity of cytodiagnosis of BCC could 
be assessed. 
The outcome measures in Paper III and Paper IV were reported somewhat 
differently. In Paper III, the calculation of 6-year complete response rate did not include 
data from the five lesions showing partial response to treatment at 3-month follow-up. 
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This way of reporting treatment results has been commonly used in many PDT studies, 
but may have led to over-optimistic results.87,112 Some researchers consider that BCCs 
reappearing within a treatment field represent a residual lesion rather than a new 
primary lesion.63,108,134  In line with this view, both incomplete responders by 3 months 
following treatment as well as later recurrences were classified as treatment failures in 
Paper IV. The proportion of treatment failures may appear to be higher by this approach 
than in similar studies that do not include the early incomplete responders. 
Long-term follow-up studies are susceptible to attrition, thus the handling of data 
from participant dropouts is important in the interpretation of results.   
The best method for estimation of lesion response to treatment over time is claimed to 
be the use of a time to event approach. Such a method has the advantage of being able 
to use all available data, including data from dropouts, to estimate the complete 
response probability.64,66,135  This approach was used in the 10-year follow-up study to 
estimate treatment response. 
A common way of reporting recurrence rates is based on the total number of patients 
with recurrent BCC divided by the total number of patients with initial lesions treated 
(raw recurrence rates).64  This approach ignores the patients lost to follow-up and may 
give an underestimation of the recurrence rate. Other long-term studies report 
recurrence rates based on the total number of patients with recurrent BCC divided by 
the total number of patients with lesions that were evaluated at the final follow-up (strict 
recurrence rate). This method may artificially raise the recurrence rate because it 
excludes patients who are cured and whose control period is shorter than the final study 
control. The actual recurrence rate is believed to be somewhere between the values 
derived from using raw or strict recurrence rates.   
In Paper III, we avoided the uncertainty of treatment response with regard to 
participant dropouts in the interpretation of our results. Two patients died very early in 
the follow-up period. No further patients were lost to follow-up. By excluding these two 
patients in the analyses, all information with regard to BCC recurrence during follow-up 
was available after the final visit. 
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According to acknowledged principles of clinical study design, the demonstration of 
efficacy of a treatment is preferably based on comparing the response in the treated 
group with that of a control group receiving placebo or another active treatment. 
Patients should then be allocated at random (randomized) to one of different treatments. 
Randomized, controlled studies provide the best evidence with minimal bias (systematic 
skrewness), particularly if blinded.132 Without a control group, as in both Papers III and 
IV, both bias and confounding (i.e. error in assessment of cause-and effect) may have 
affected the results. Even so, these studies may give information on extent and duration 
of treatment effect and suitable treatment strategies. 
Many of the early studies on topical PDT of BCC have a limited follow-up period. 
The strength of Papers III and IV is the close and long follow-up after treatment. 
Treatment efficacy was found to be much higher in lesions receiving two treatment 
sessions compared to those receiving only one. For practical reasons the number of 
treatments was changed from two to one PDT session halfway through the treatment 
period of one year. In a sense the allocation to treatment could be regarded as “random” 
in the popular meaning of the word, as the number of treatment sessions given was not 
determined by individual considerations, but by the point in time at which the treatment 
took place. However, since the lesions were not appropriately randomized to one or two 
treatment sessions the results should be interpreted with caution.  
In Paper 1, all the cytological smears were evaluated in a blinded and random order 
before being compared with the histopathology report that was regarded as the “gold 
standard”. In the interpretation of the cytological smears observer variability may be a 
source of uncertainty in the evaluation of cytology as a diagnostic test. Thus the 
question of reproducibility of the results may be raised. Strength of this study is that two 
pathologists with extensive experience in general cytology evaluated the smears and 
imprints. Bias may have been introduced when obtaining the cell material, however, as 
the sequence of sampling may have influenced the quality of the smears and imprints. 
The first skin scrape smear from each lesion was stained with Pap and the second with 
MGG. Imprints were always made after skin scrape sampling, which further may have 
reduced the availability of representative material. This is an evident weakness of this 
study design.
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Results 
In Paper I, skin scrape cytological diagnosis showed a high sensitivity and specificity 
for BCC and differentiated well between BCC and AK. The satisfactory agreement 
shown between cytological and histological diagnosis in BCC is consistent with the 
results reported in a systematic review of the literature on this area from 2004.53 The 
pooled sensitivity and specificity of cytodiagnosis in BCC was reported to be 97% (95% 
Cl 94-99) and 86% (95% Cl 80-91), respectively. The studies eligible for this review, 
including information of the staining techniques that were used in each study, are shown 
in Table 2. The review does not conclude with regard to which of the staining 
techniques was the most suitable.  
 
 
Table 2.
Studies of skin scrape cytological diagnosis of BCC where histopathology was used as 
“gold standard”  
                                        
Study   Year Sample    
size 
Staining technique 
Brown CL et al.139 1979 131 MGG  
Gordon LA and Orell SR137       1984 150 Pap 
Böcking A et al.144 1987   37 Pap 
Ruocco V143               1992 498 MGG/Pap/Giemsa 
Derrick EK et al.142               1994 246 MGG 
Barton K et al.145                 1996   20 Pap 
Berner A et al.54               1999 112 Diff-Quick * 
Vega-Memije E et al.136     2000   15 Pap 
*Diff-Quick is a MGG stain variant utilized on material which is air dried 
(Provided by Christensen E.) 
 
    
The results in Paper I show that Pap and MGG stain may be equally well used in the 
diagnosis of BCC. The sampling of cell material on to the glass slides was done after 
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careful removal of any keratotic layer covering the lesion using a small curette. Only 
2.6% of the skin scrapes were considered to be non-evaluable as compared to 4.5, 6 and 
13% in previous studies.54,136,137 Adequate sampling is required to achieve good results 
as unsatisfactory and non-representative smears can give false negative cytological 
diagnostic results.138,139 Slightly more of the MGG stained smears were regarded as 
non-evaluable compared to Pap stained smears (Paper I) (Figure 8). To compare the 
diagnostic ability of Pap and MGG stain more appropriately, the order of sampling of 
cell material from individual lesions for Pap or MGG staining should have been 
randomized. The diagnostic result of touch imprint cytology may, to an even greater 
extent than MGG skin scrape, have been affected by the order of sampling. Almost one 
third of the imprints had too sparse material for diagnosis. Of the remaining 
representative slides, however, 97% of BCCs were correctly identified. Touch imprint 
cytology has been demonstrated to agree 100% with cytohistopathological examination 
when smears were prepared by touching the cut surfaces of excised BCCs on to the 
slides.140 However in another study, touch imprint cytology was reported to be positive 
for BCCs in only about 50% of the investigated cases.141 Further studies are needed to 
determine the role of touch imprint cytological diagnosis in BCC.  
Punch biopsy specimens for histological diagnosis were regarded as “gold standard” 
for the diagnosis of BCC, and used for cytodiagnostic comparison. This was done even 
though a small biopsy specimen taken from a selected lesion area may not be 
representative of the whole BCC. An advantage of skin scrape cytology is that 
representative material from the entire surface of the lesion may be sampled and 
investigated. This makes skin scrape cytology particularly useful in diagnosing 
superficial BCC. If cytology is negative in a lesion clinically suspicious of malignancy, 
it is still possible to take a biopsy specimen for histological examination. Furthermore, 
cytological smears can easily be prepared from the curetted and/or debulked material 
obtained during PDT preparation, to confirm the BCC diagnosis in those cases no prior 
confirmation of the clinical diagnosis exists. However, skin scrape cytology can not be 
used to determine BCC thickness and has not been shown to differentiate between BCC 
subtypes. Cytology also has limitations in differentiating between BCC and other 
adnexal tumours.38  
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In Paper II, we found an overall reasonable agreement between the mean (average) 
measurements of BCC thickness of the two groups. This suggests that the mean 
(average) punch biopsy thickness may be used to approximate the mean (average) 
thickness of BCC, which can be useful in relation to scientific work. In daily practice, 
however, the thickness of the individual BCC is of the utmost clinical relevance. BCC 
thickness has received particular attention along with the introduction of topical PDT. A 
pre-treatment lesion biopsy for histopathological investigation is recommended by the 
Norwegian practical PDT guidelines.105 It is currently a supportive diagnostic method 
often used in clinical practice and can provide information for selection of BCCs suited 
for PDT. Based on a systematic literature review, the current international PDT 
consensus guideline recommends the use of topical PDT for BCCs with a thickness up 
to 2 mm.112 
 We found that thickness measurements in punch and excision biopsy specimens 
from individual BCCs may differ considerably and, moreover, that this disparity 
increased with increasing tumour thickness. Based on the data in Paper II, a pre-
treatment tumour thickness biopsy measurement of up to 1 mm suggests that the BCC 
most likely will be within the limit of the international consensus guideline with regard 
to thickness. BCCs that on biopsy measure more than 1 mm, however, may well exceed 
this limit. Thus, information on tumour thickness returned from histological 
investigation of a biopsy specimen appears, in some cases, to be insufficient for 
appropriate selection of treatment.  
Although not directly comparable to results in Paper II, the relationship between 
punch biopsy and excision specimen tumour thickness in SCC of the lower lip has been 
investigated. This study also demonstrated considerable disparity between the two 
sampling methods. This discrepancy was particularly evident in tumours that were 
greater than 3 mm thick.146   
New imaging techniques for non-invasive investigation of skin tumours, such as 
OCT and HFUS, can be used to estimate BCC thickness.55,147 In a study comparing 
HFUS and OCT to determine BCC thickness in 10 lesions, OCT agreed better with 
histopathological tumour thickness (the “gold standard”) than HFUS.148  Similarly, in 
another study investigating tumour thickness in 62 BCCs, OCT appeared to correlate 
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better with histology than HFUS.55 With HFUS, tumour thickness has been shown to be 
overestimated, because subtumoural inflammatory infiltrates cannot be differentiated 
sufficiently well from tumour tissue by use of this technique. OCT, on the other hand 
has been demonstrated to both over- and underestimate tumour thickness. Due to scatter 
of light in tissue, the imaging effect of OCT is limited to a depth of approximately 1 
mm.55,149 Hence, OCT is currently insufficient for pre-treatment characterization of 
BCC thickness. However, it offers the possibility to provide an impression of several 
morphological characteristics, whereas HFUS does not differentiate properly between 
different skin lesions. So far, these technologies are considered experimental in the 
characterisation of BCC thickness. Histopathological examination of BCC is therefore 
the reference standard.  
Punch biopsy is a well established technique used to obtain full-thickness diagnostic 
tissue.49 With this technique tissue architecture is well preserved, and even punches 
with small diameter provide material of sufficient size and quality for reliable 
histological diagnosis.50 In Paper II, both punch- and excisional biopsy provided 
adequate tissue samples for the investigation of deep tumour margin in almost all cases. 
Nevertheless, the possibility of not establishing the “true” maximum tumour thickness 
in a given BCC either by examination of punch biopsy or surgical excision specimens 
remains. A punch biopsy specimen only represents a small part of the total tumour area 
and, even in excisional biopsy only limited sections of the specimen are prepared for 
microscopic examination.150 As the excision in this study always followed immediately 
after the biopsy punch, any error in the evaluation of tumour thickness due to changes 
of tumour over time (e.g. regression or growth) was eliminated.  
The overall BCC complete response rates after 6 and 10 years were 81 and 75%, 
respectively (Papers III and IV). All treatment failures were noted within 3 years of 
treatment. These results are similar to long-term results of other ALA- and MAL-PDT 
studies and give further evidence in support of topical PDT as an attractive treatment 
option with sustained high efficacy for treatment of BCC (Table 3).  
 
 53
Table 3.  
Studies of histologically or cytologically verified BCC with 3- or 5-year follow-up after 
topical PDT  
 
Study Design n P
R 
Subtype Lesion
preparation 
Treatment Follow-up 
(years) 
CR rate 
(%) 
Basset-
Seguin
161
Prospective 
RCT
60 P sBCC Sligth debride-
ment
MAL-PDT 5 75 
Rhodes
135 Prospective 
RCT
53 P nBCC Curettage MAL-PDT 5 76 
Souza
160 Prospective 15 P 
R
sBCC 
nBCC
Non DMSO-EDTA 
ALA-PDT
5 64 
Star
151
 Prospective 86 P sBCC Salicylic acid  
10 % 
ALA-PDT Mean 5 84  
Mosterd
134
 Prospective 
RCT 
85 P nBCC Debulking ALA-PDT 3 70  
Solér
107
 Retrospective 350 P 
R 
sBCC 
nBCC 
Curettage/ 
debulking 
MAL-PDT Mean 3 79  
Baptista
152
 Prospective 70 P sBCC 
nBCC 
Non ALA-PDT Mean 3  71  
RCT = randomized controlled trial, P = primary BCC, R = recurrent BCC, sBCC = superficial BCC,  nBCC = nodular BCC,                
CR = complete response, n = number of BCC treated with topical PDT 
(Provided by Christensen E.)   
 
 
Both ALA- and MAL-PDT are proved to be effective in BCC.87,112 There is little 
published clinical data comparing ALA- and MAL-PDT, but in a small, randomized 
study of nodular BCCs, no significant difference in efficacy was found.94 A direct 
comparison of various study results is difficult because of differences in study design 
with use of different topical photosensitizes, light sources, treatment sessions, pre-
treatment and inclusion of different BCC subtypes. In addition, different definitions of 
treatment failure yield different results. This point is clearly demonstrated with the 
disparity between complete response rates found in the 6- and 10-year follow-up, 
despite the fact that no new cases of treatment failure was noted during the last 4 years 
of the 10-year study.  
In the treatment of BCC, curettage can be combined with other modalities such as 
surgery, electrodessication and cryosurgery, to delineate tumour margins and to reduce 
tumour thickness.153-155 Curettage may also be used alone.156 In Papers III and IV, a 
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particularly high complete response rate of at least 90% was shown in primary BCCs 
receiving two PDT-sessions. The pre-PDT preparation may have contributed to this 
outcome. This preparation included debulking of thicker tumours. The purpose of 
debulking was not to remove all parts of the tumour, only to remove the main tumour 
bulk within clinical margins. The pre-PDT preparation also included curettage of the 
perilesional area to minimize the risk of recurrence from subclinical BCC 
extensions.157,158  
The use of DMSO may have further contributed to the favourable outcome by 
initiating ALA-induced porphyrin production122 and by enhancing ALA-PDT 
penetration in the BCC.119  A favourable short-term treatment outcome has previously 
been demonstrated in a study using DMSO-EDTA-ALA-PDT and two different light 
sources.159 The 6-month complete response rate in superficial BCC was more than 80% 
in both groups.  In another study using DMSO-ALA-PDT in nodular BCC, the mean 
17-month response rate was 95% in those BCCs having a clinical complete response 3 
to 6 months after intervention. However, a complete response rate of only 64% was 
demonstrated in a 5-year follow-up study after DMSO-EDTA-ALA-PDT.160 In this 
study, both recurrent and nodular BCC were included, no pre-PDT preparation was 
performed and only one treatment session was given. 
Results after treatment with various standardized therapies are also difficult to 
compare with PDT results, because of the lack of uniformity in study design such as 
inclusion criteria and different treatment protocols.64 Setting this point aside, the high 
and sustained PDT efficacy demonstrated in Papers III and IV, particularly in BCCs 
having received two PDT sessions, is comparable with long-term results after various 
non-MMS treatments for this type of skin cancer.63,66  Five-year recurrence rates 
following excisional surgery, curettage with electrodessication, radiotherapy and 
cryotherapy are reported to be between 5 to 10%, 8 to 13%, 4 to 16% and 8 to 26%, 
respectively.58,63,66,161 Overall five-year treatment response of superficial BCC following 
imiquimod cream 5% is reported to be about 80%.162,163 
The cumulative recurrence rate following surgery, radiotherapy and curettage and 
electrodessication in BCC also show that 50% of recurrences are identified within 2 
years and 66% are diagnosed within the first 3 years of treatment.63 After use of topical 
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PDT, it appears that the majority of recurrences occur during the first years. In Paper IV, 
87% of recurrences appeared within 2 years and no further recurrences were observed 
beyond 3 years of follow-up.  This observation is consistent with results from other 
long-term follow-up PDT studies that, with few exceptions, report recurrence of BCC to 
present itself within 3 years after treatment.134,135,160,161  
A randomized, controlled study design is preferred when analysing treatment effects. 
A few randomized studies comparing topical PDT efficacy with other traditional BCC 
therapies have been published.134,135,161,164-167 With the exception of one study, surgery 
was more effective than PDT, but no significant difference between cryosurgery and 
PDT was found. No difference in treatment efficacy after 12 months was observed when 
comparing ALA-PDT with cryotherapy in mixed BCCs in an early study from 2001.164 
A similar result was later found with curettage and MAL-PDT; the 5-year complete 
lesion response rate in the MAL-PDT group was estimated to 75% compared to 74% in 
the cryotherapy group.161 Five other studies report on follow-up results after treatment 
with either topical PDT or excisional surgery of BCC. The first study demonstrated a 5-
year sustained lesion cure-rate for surgery of 96% compared with 76% for MAL-
PDT.135  The second found a 3-year treatment failure of 2% for surgery compared to 
30% for ALA-PDT.134  In the third study, small superficial BCCs were treated. This 
study showed a recurrence rate of approximately 9% in the MAL-PDT group and no 
recurrence in the surgery group after 12 months.165 The fourth study reported 38% 
treatment failure in the ALA-PDT group and 21% failure in the surgery group 12 
months after treatment of nodular BCC.166 In the fifth study, ALA-PDT was 
demonstrated to be as effective as excision surgery after treatment of 94 superficial and 
nodular BCCs with a mean follow-up period of 25 months.167  
In addition, PDT has been shown to be more effective in the treatment of nodular BCC 
than placebo. Two multicentre, randomized, double-blinded studies comparing MAL-
PDT with placebo cream, found treatment response rates of 73 and 27%, respectively.168  
Treatment efficacy is one among several factors that determine the choice of therapy 
for the treatment of BCC. As BCC often arise in cosmetically or functionally important 
areas, many clinical considerations and patient’s needs should be taken into account 
when deciding on treatment method.73,78,169,170   PDT has shown long-term superior 
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cosmetic outcome when compared to treatment outcome by more invasive treatment 
modalities.134,135,161,164 The prospect of better cosmetic outcome has been reported to 
influence patient preference in favour of PDT over surgical excision for treatment of 
BCC.170 Cosmetic outcome has in previous studies been rated as good or excellent from 
87 to 100% at 3 and 5 years after PDT.107,135,160,161  The attractive post-treatment 
cosmetic results demonstrated in Papers III and IV add evidence to these results.  
Three-month clinical examination of treatment areas after PDT is reported to 
overestimate the response compared with histology.118,164,171 The clinical complete 
response rates are previously shown to range from 87 to 95% compared to histological 
results ranging from 50 to 85%. On the other hand, histological investigation of biopsy 
tissue from treated areas, clinically evaluated to be in complete response at 12 and 32 
months after PDT, appeared to be of limited value (Papers III and IV). By use of 
histology, only one additional remnant BCC was revealed that was missed by clinical 
investigation. Further, even though the histology 12 months after treatment was 
negative, three recurrent BCCs appeared at a later time. It cannot be ruled out that the 
punch biopsies were taken from areas that were not representative of the residual 
tumour, as the histopathological specimens were obtained using 2 or 3 mm punches that 
necessarily can not sample the whole area of the original BCC. The benefit of possibly 
detecting a few recurrent tumors earlier by histological investigation rather than by 
clinical examination of the treatment areas should be weighted against the drawback of 
taking multiple biopsies as part of the follow-up procedures. The present study results 
and knowledge of BCC to be slow growing and with extremely low potential to 
metastasize, suggest that clinical examination of the treatment areas suffice for long-
term follow-up.  Patients should, however, be encouraged to perform self-examination 
and be advised to consult a medical doctor if they notice changes in treated areas.  
Various patient- and lesion-related factors are reported to be associated with 
treatment failure.58,78 Factors that might be associated with failure after PDT were 
explored in Papers III and IV. Some patients presented with more than one BCC. In 
Paper III, initially all lesions were handled independently as traditional statistical 
methods require that observations are independent. This strategy was chosen in order to 
utilize all available information, and because multiple BCCs within the same patient 
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often were of various subtypes and with different body location. However, research has 
provided an increasing knowledge of anti-tumour immune response after PDT. The 
direct damage of abnormal cells initiates a variety of the host’s response strategies, such 
as inflammation and activation of innate and adaptive immunity that may affect the 
results.86 As a consequence, the data were re-analyzed. When using a robust variance 
model that takes clustering of lesions into account, the association of gender and H-zone 
with treatment failure was even more significant than the first reported values.  
Treatment failures were more frequent in men than in women. This has not, to our 
knowledge, been found in previous PDT studies reporting on gender. Data on sex 
differences in BCC are scarce, but evidence show that men have a higher incidence of 
BCC than women.3,172,173 Also, men have been known to have deeper invasion of 
tumours, dissimilar tumour localisations, and men are more prone to develop BCC in 
response to other factors than women.20,34,173,174 Some studies report higher BCC 
recurrence in men than women after MMS and radiotherapy.175,176 It has been 
speculated that more prominent male hair follicles may contribute to deeper BCC 
growth into tissue.34  
Patients’ age and use of immunosuppressive medication were factors not found to be 
related to an increased risk of BCC relapse. This is in line with a few other PDT studies 
reporting on treatment failure in relation to patient’s age.108,134  However, in a recent 
Danish publication, patients over the age of 60 had significantly higher recurrence rates 
compared to younger patients.177 Publications on PDT efficacy in the treatment of BCC 
in immunosuppressed patients are scarce. The short-term remission rate in a study of 32 
(mainly BCC) facial tumours treated with PDT is shown to be 75%.178 However, in a 
recent MAL-PDT study of 18 organ-transplant recipients, Guleng and Helsing179 
achieved a BCC recurrence rate of only 6% with a mean follow-up of 22.6 months. 
Recurrent lesions (failures of previous treatment) are considered to be high risk lesions 
and are often of the histological aggressive types.2 PDT is not regarded as a first line 
treatment of such lesions.58,180 As many as three out of five recurrent BCCs did not 
completely respond to PDT within the 3 first months (Papers III and IV). Also in a 
recent PDT 3-year follow-up study the cure rate for recurrent BCC was low, estimated 
to 63%.181 Interestingly, after treatment with PDT with a mean follow-up of 22 months, 
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Solér et al.182 achieved a cure rate of 82% in BCCs that previously had recurred after 
radiotherapy.  However, a pre-PDT skin shaving procedure and up to five treatment 
sessions were performed in this study.  
It is suggested that BCC lesions located within the H-zone are generally more 
difficult to treat, regardless of method, due to the potential of BCC growth into 
unexpected depths along embryonic fusion planes.79,158,183,184 However, this theory has 
not been proven. BCC location within the H-zone was found to be associated with 
recurrence of tumour after PDT in Paper III, but not in Paper IV. This is an illustrative 
example of how much an apparently small change in analyses strategy can affect the 
results. With topical PDT in BCC, several studies have failed to demonstrate a 
difference in treatment response by site.108,134,165,185  PDT has even been shown to be 
most effective for facial lesions, as reported in a study by Foley et al. using minor 
debulking and MAL-PDT in nodular BCC. On the other hand, Solér et al. reported a 
complete response rate of 76% in BCCs located to the H-zone compared to a rate of 
92% for tumours located outside this zone, in a curettage and MAL-PDT study of a total 
of 350 superficial and nodular BCCs.107 Of concern is that the H-zone area appears to be 
defined somewhat differently as it is marked with slight variation on figure illustrations 
in different publications.62,78,105,183 Differences across studies whether a lesion is inside 
or outside this zone can occur and may have affected the various results.  
In Papers III and IV, the majority of BCCs were considered to be small ( 2 cm), 
thus the conclusion only applies to small lesions. The only lesion larger than 2 cm 
resulted in treatment failure. There is evidence indicating that larger BCC have higher 
recurrence than smaller lesions after PDT, but the size limit varies in the different 
studies.161,168,171,184  
BCC thickness or subtype was not found to be associated with treatment failure after 
PDT (Papers III and IV). In the long-term follow-up results, we demonstrated a 
complete response rate of 82% in tumours more than 2 mm thick. Only a few studies 
have investigated the influence of BCC thickness on PDT outcome, and the results 
returned from these studies are ambiguous.107,108,134,168 In a study by Morton et al.185, 
BCC thickness was showed to affect treatment response significantly. ALA-PDT was 
performed without pre-treatment preparation of the treatment area. No tumours with 
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thickness more than 2.0 mm showed complete response.  In a recent study by Fantini et 
al.108 using MAL-PDT in BCC, tumour thickness was also shown to have an impact on 
treatment response, with lower cure rates with increasing tumour thickness. The overall 
complete response was 62%; 33% for nodular BCC, but no tumour debulking was 
performed.  In another study, comparing curettage and MAL-PDT with placebo and 
curettage, treatment response in the PDT group proved slightly less effective in BCCs 
with baseline thickness more than 1.0 mm. Nevertheless, 82% complete response of 
tumours measuring from 2.0 to 5.0 mm thick was reported.168  In a curettage and ALA-
PDT study of thick nodular BCCs, no significant difference of BCC recurrence was 
found according to whether tumours were thinner or thicker than 1.3 mm.134 The 
comment presented by the authors with regard to this finding, was that the thickness 
measurements from a biopsy specimen might not be representative for tumour thickness 
of the entire lesion. This view is supported by the findings in Paper II.  
 Furthermore, pre-PDT curettage and debulking may significantly reduce BCC 
thickness.124 Thus, the pre-treatment preparation should be described in detail as this 
procedure may have a great influence on the treatment outcome. This information is 
often either lacking or insufficiently described in many publications. Information on 
BCC thickness is usually based on histological examination of a diagnostic biopsy 
specimen. However, a pre-treatment biopsy may not represent the BCC thickness at the 
time of treatment. Thus the pre-treatment thickness measurement may be misleading in 
the assessment of PDT effect with regard to BCC thickness. This caution also applies to 
results in Papers III and IV. 
 Different histological methods for BCC subtype classification were used in Papers I-
IV. In Paper III, tumours were classified into superficial or nodular types, based on 
growth down to or below the papillary dermis.129 Such a classification is currently 
rarely in use as it only provides information about the growth-depth and not the 
morphologic growth type. In Paper IV, BCC were classified into aggressive and non-
aggressive subtypes, based on histologic growth pattern.31 No significant association 
was found between treatment failure and subtype, defined by any of these two 
classification methods. Although histological examination is the basis for subgroup 
analyses, the information provided from a biopsy can still be limited. According to the 
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literature, punch biopsies are accurate in predicting BCC subtype in only 69 to 89% of 
cases.186-188    
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CONCLUSIONS  
 
x Cytological skin scrape diagnosis for BCC was dependable. 
 
x There was no significant difference in sensitivity between Pap and MGG stain 
for skin scrape cytodiagnosis in BCC. 
 
x Touch imprint cytology was not found useful as a routine diagnostic method. 
  
x Reasonable overall agreement was found between mean (average) BCC tumour 
thickness in punch biopsy and excision specimens.   
 
x Predicting BCC thickness from a single punch biopsy of individual lesions could 
be inaccurate: increasing with increasing BCC thickness. 
 
x High treatment efficacy and favourable cosmetic outcome was achieved 6 years 
after two sessions of topical DMSO-ALA-PDT in BCCs that showed complete 
clinical cure 3 months after treatment.  
 
x All BCC recurrences appeared within 3 years after treatment. 
 
x Recurrent BCC, male gender, one treatment session and lesion location within 
the H- zone were factors associated with treatment failure after topical PDT. 
 
x Two sessions of curettage and topical DMSO-ALA-PDT gave a 10-year high 
and sustained efficacy with a favourable cosmetic outcome in small and primary 
BCCs. 
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CLINICAL IMPLICATIONS 
Given the magnitude of BCC, the need for better diagnostic and therapeutic approaches 
is continuous.  
Skin scrape cytology with either Pap or MGG stain, is a diagnostic method to be 
considered for confirmation of clinically suspected superficial BCCs suitable for non-
invasive treatment modalities such as topical PDT, and of clinically suspected BCC 
relapses following PDT. A high degree of representative cell material can be obtained 
by careful scraping the surface of the lesion with a small curette after removal of the 
keratotic surface. Cytodiagnosis can also be performed on cell material obtained as part 
of the PDT pre-treatment procedure when no prior histological diagnosis is available. 
Prior knowledge on tumour thickness is important for selection of BCCs suitable for 
topical PDT. BCC thickness measurements from single 3 mm punch biopsy specimens 
may not be representative of the thickness of the whole tumour, and thus insufficient for 
planning of therapy in some cases. With a punch biopsy tumour thickness measurement 
of 2 mm or more, the BCC is thicker than the current recommended limit for topical 
PDT, according to the international PDT consensus guideline. A measurement of 1 mm 
or less suggests that the tumour most likely will be within the recommended limit for 
PDT.  However, with a measurement between 1 and 2 mm the true tumour thickness 
may well exceed the current recommendation. In such cases the choice of therapy may 
be reconsidered. Should the indication for PDT be compelling, despite uncertainty with 
regard to tumour thickness, supplementary biopsies may be taken before treatment 
and/or a close follow-up after PDT may be prescribed.  
Two sessions of curettage and topical DMSO-ALA-PDT give a high treatment 
efficacy in selected primary, small BCCs and with a favourable cosmetic outcome. 
Most failures occur within 3 years follow-up. Based on our studies, histopathological 
examination of specimens from small punch biopsies from treated areas in clinical 
complete response is of limited value in long-term follow-up.   
.   
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ERRATA
The flow chart (Figure 1) in Paper III contains misprints. The number of patients with 
lesions showing partial treatment response at 3 months should be n = 4 and the number 
of patients with recurrence at 36 months should be n = 1. These mistakes propagate 
further in the chart. However, the numbers of lesions in the chart are correct. The 
second last “assessment box” below 24 months should read 36 months. 
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Tumour thickness affects the outcome of photodyna-
mic therapy in basal cell carcinoma (BCC). The aim of 
this study was to evaluate whether punch biopsy provi-
des reliable information on BCC tumour thickness, by 
comparing corresponding measurements in biopsy and 
excision specimens for 48 lesions in 43 patients. BCC 
tumours were between 0.2 and 6.1 mm thick. The mean 
depth of the excisions were 0.14 mm greater than that 
of the biopsies. Bland-Altman 95% limits of agree-
ment were (–1.3, 1.6) mm, but the difference between 
measurements increased with tumour thickness. A punch 
biopsy tumour thickness of 1.0 mm yielded an upper 
95% predicted limit for excision depth within 2.0 mm. 
In conclusion, there was reasonable overall agreement 
between corresponding measurements. A biopsy thick-
ness of 1.0 mm suggests that the tumour will most likely 
be within the current accepted limits for photodynamic 
therapy. With increasing tumour thickness, however, 
individual tumour measurements may differ considera-
bly. Key words: skin cancer; basal cell carcinoma; tumour 
thickness; biopsy punch; microscopic measurement; topi-
cal photodynamic therapy.
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Basal cell carcinoma (BCC) is the most common type of 
skin cancer in the adult, white population and has an in-
creasing incidence worldwide (1, 2). It is a slow-growing 
tumour that can show infiltrative irregular extensions and 
outgrowths on histological examination (3, 4). Despite its 
low metastatic potential, this tumour can cause significant 
local tissue destruction and patient morbidity (5). Given 
that BCC has a predilection for sun-exposed skin on the 
head, face and neck, cosmetic outcome may be important 
when choosing therapy (6, 7). 
Topical photodynamic therapy (PDT) has shown 
cosmetic superiority over traditional therapies including 
surgical excision (8, 9). It involves the accumulation 
of a photosensitizer in neoplastic tissue, which is then 
activated by red light, thus inducing a photochemical 
reaction that results in tissue destruction (10, 11). 
Tumour thickness is an important predictor of meta-
stasis in malignant melanoma (12) and squamous cell 
carcinoma (SCC) (13, 14); in BCC it may affect the 
response to PDT (15–19) since this therapy has limited 
skin-penetrating abilities (20). The photosensitizers 
most commonly in use have been shown to penetrate 
BCC tumours efficiently to a depth of only approxima-
tely 2.0 mm (20–22), and red light also has a limited 
penetration into tissue (23). Several studies have demon-
strated lower PDT response rates in nodular tumours 
compared with superficial lesions (15, 17, 23–25). 
There fore, current guidelines preferentially recom-
mend the use of topical PDT for thin lesions (10, 26), 
and hence support the need for reliable pre-treatment 
assessment of BCC tumour thickness (27).
In addition to an accurate diagnosis, a biopsy spe-
cimen for histopathological examination provides in-
formation about the depth of tumour invasion and the 
histological growth pattern (28–30).
Punch biopsy is widely used and is generally con-
sidered the primary technique to obtain full-thickness 
diagnostic tissue (31). With this technique tissue ar-
chitecture is well preserved, and even small diameter 
samples provide material of sufficient size and quality 
for reliable histological diagnosis (32). However, a 
biopsy punch will offer information from only a res-
tricted selected tumour area compared with an excision 
specimen, which allows more extensive examination of 
a lesion. One may thus question the ability of a single 
biopsy reliably to reflect tumour depth in a given lesion. 
It is therefore of clinical and scientific interest as to 
whether biopsy measurement of tumour thickness is an 
accurate basis for treatment planning and apposite as a 
reference in research work.
The aim of this prospective study was to evaluate 
whether punch biopsies provide reliable information 
about BCC tumour thickness, by investigating the agree-
ment between measurements made on punch biopsy and 
excisional specimens from the same lesions.
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MATERIALS AND METHODS
Patients referred to the outpatient clinic at the Department of 
Dermatology, St Olav’s University Hospital, Trondheim, with 
primary tumours clinically suggestive of BCC and suitable for 
excision surgery were assessed for eligibility. Exclusion crite-
ria were: age less than 18 years; pregnancy or breastfeeding; 
lesions with a clinically largest diameter less than 9.0 mm; 
lesions in which excision surgery by a plastic surgeon was the 
treatment of choice. 
Lesion sizes were clinically defined as the mean of the length 
and width measurement. Local anaesthesia, using lidocaine 1% 
with adrenaline, was infiltrated intradermally before taking of 
samples. A sterile, steel, disposable biopsy punch (Kai Industries 
Co. Ltd, Gifu, Japan) 3 mm in diameter, was used in all cases. One 
punch biopsy was obtained from each lesion prior to the surgical 
excision of the same lesion. Three dermatologists performed this 
procedure, each on 24, 19 and 12 lesions, respectively. 
The biopsy punch was taken from the part of the tumour that 
was clinically considered to be thickest by inspection and pal-
pation. If the tumour appeared to be homogeneous, the biopsy 
was taken from the central area. After obtaining the punch 
biopsy, the whole tumour was excised using a full-thickness 
ellipse resection. Corresponding punch biopsy and excisional 
specimens were obtained in all cases, and examined by one 
hospital pathologist. 
The depth of the punch biopsy tissue was routinely measured 
after fixation in formaldehyde. The tissue was further subjected to 
a dehydration process by immersion in increasing concentrations 
of ethanol, clearance in xylene and, finally, casting in paraffin 
wax to make it stable and easy to cut with a microtome. 
The punch biopsy was oriented so that the epidermis aligned 
with the longest axis of the wax block. Three parallel, intersper-
sed sections were cut out of the block. The sections were stained 
with haematoxylin, eosin and saffron (HES) and examined under 
a microscope. The thickness of the tumour was measured from 
below the stratum corneum to the bottom of the tumour nest. 
Tumour thickness and investigation of disease-free deep margin, 
defined as at least 0.1 mm of tumour-free tissue, were based 
on measurements using an ocular micrometer (Pierre Verniers 
method) to a precision of  0.1 mm (28). The largest measurement 
of the three histologically prepared sections from each punch 
biopsy specimen was defined as the punch tumour thickness. 
The surgically removed excision specimen was oriented by an 
attached suture before being cut into 3–8 slices in accordance 
with the breadloaf sectioning method (33). The number of slices 
was dictated by specimen size, each with a thickness of 2–3 
mm. Following the same procedure as for punch biopsy, the 
3–8 slices were processed and cast into 2–3 blocks of paraffin 
wax. Sections representative of both central and peripheral areas 
of the lesion were cut from the blocks. Assessment of tumour 
thickness and investigation of disease-free surgical margins 
were carried out as described for the punch biopsy specimen. 
The largest measurement obtained in the histologically prepared 
sections from a surgical excision specimen was defined as the 
excisional tumour thickness.
The excisional specimens were histologically subclassified 
into three categories; superficial, nodular, and aggressive-
growth types. The last category included the morpheiform, 
infiltrative and basosquamous types (34). 
The study was approved by the local ethics committee (REK 
number 4.2007.558) and patients provided written informed 
consent prior to study entry.
Statistical methods
The agreement between punch biopsy and excision specimen 
tumour thickness measurements was investigated in several 
ways. First, the mean difference (i.e. bias) between methods was 
analysed using a paired samples t-test. Secondly, each method 
of measurement was plotted against the other, and their diffe-
rence against the mean in a Bland-Altman plot (35). This plot 
allows a visual expression of how well the two methods agree 
across the range of measurements, and provides 95% limits 
of agreement. Finally, as punch biopsy will always precede 
excision of the tumour, we obtained 95% prediction limits for 
excision tumour thickness given punch biopsy measurements 
employing the regression approach described by Carstensen 
(36). This method can take an increasing standard deviation 
into account. 
Different lesions from the same patient were considered to 
be independent, and the statistical software R (37) 2.11.1 was 
employed for all analyses.
RESULTS
Fifty patients, with a total of 55 lesions clinically sug-
gestive of BCC, were initially included in the study. 
On histological examination, five lesions proved to 
represent actinic keratosis or SCC, lymphoma in one 
case, and a benign naevus in one case. These seven 
lesions were excluded; thus 48 lesions from 43 patients 
(21 women with 23 lesions, 22 men with 25 lesions) 
were included. Mean patient age at presentation was 
74 years (range 47–97). Thirty-nine patients presented 
with one lesion, three had two lesions and one had three 
lesions. Most lesions (n = 28) were located on the trunk. 
The remainder were located in the head and neck region 
(n = 14), or on the extremities (n = 6). Mean lesion size 
was 11.59 mm (range 7.5–18.0 mm). Histologically, 
19 tumours were of superficial, 18 of nodular and 11 
of aggressive-growth type. The length of the biopsy 
specimens ranged from 2.0 to 11.0 mm, with a mean 
length of 5.3 mm. 
Tumour thickness could not be determined with certa-
inty in three biopsy and two excisional specimens from 
five different lesions, as tumour tissue was observed 
within the deepest part of the histologically prepared sec-
tions. In these cases a measurement was taken from below 
the stratum corneum to the lower part of the section. 
The mean punch tumour thickness was 1.53 mm (range 
0.2–5.2 mm), and mean excisional tumour thickness was 
1.67 mm (range 0.3–6.1 mm); yielding a mean difference 
between measurements (i.e. the bias) of 0.14 mm.
We found identical (within 0.1 mm) measurements 
of tumour thickness using the two methods in 7 lesions. 
Surgical excision gave the largest measurement in 23 
(55%) of 41 specimens. For tumours less than 2.0 mm 
thick, surgical excisions gave the largest measurement 
in 61% of cases. For tumours equal to or thicker than 2.0 
mm either method yielded the largest measurement.
Fig. 1 shows the Bland-Altman plot with 95% limits 
of agreement (–1.33 mm to 1.6 mm) for the difference 
between the two measurements. The plot shows a wi-
dening scatter as the average thickness increases, i.e. an 
increasing disparity between the two methods. 
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Figs 1 and 2 clearly demonstrate that the difference 
between measurements increases as tumour thickness 
increases; this was confirmed in the regression analysis 
(p < 0.01). Fig. 2 shows the scatter plot of punch biopsy 
vs. excision specimen measurements, including the up-
per 95% limit of prediction. 
Interpretation of Fig. 2 is as follows: with a punch 
biopsy tumour thickness of 1.0 mm, the corresponding 
excision tumour thickness will, with 95% probability, be 
less than approximately 2.0 mm. With a punch biopsy of 
2.0 mm, the limit is 3.5 mm; and with biopsy measure-
ments beyond 2.0 mm the limits diverges strongly.
DISCUSSION
The accuracy of pre-treatment tumour thickness assess-
ment in BCC is of importance to ensure an adequate 
selection of lesions suitable for PDT. 
In the present study, we have described and quantified 
the agreement between corresponding measurements 
of BCC tumour thickness in punch biopsy and surgical 
excision specimens.
The mean depth of the excisions were 0.14 mm 
greater than that of the biopsies. The disparity between 
the two methods, however, increased with increasing 
tumour thickness.
The true extent of tumour thickness is unknown, as an 
accurate measurement of the thickest part of tumour is 
not always available. The surgical specimen cannot be 
regarded as a “gold standard”, first because the biopsy 
punch may have removed the thickest tumour area. Se-
condly, in accordance with standard histopathological 
examination merely limited sections of the excision 
specimens were made, hence the risk of not detecting 
maximum tumour depth (33). 
The clinical and histological diagnosis agreed in 87% 
of all biopsied lesions in this study. This is in line with 
previous studies that show the clinical diagnosis to be 
inferior to the histological diagnosis in BCC (30, 38). 
The punch biopsies were given priority, in the sense 
that they were taken prior to the excisions and from 
the thickest part of the tumour according to the clinical 
evaluation. Nevertheless, the largest tumour thickness 
was slightly more often found by surgical excision. Both 
techniques provided adequate tissue samples, including 
sufficient representative material for the investigation 
of deep tumour margins in almost all cases. 
A variety of diagnostic technologies, such as optical 
coherence tomography and high-frequently ultrasound, 
are under investigation for non-invasive diagnosis of 
non-melanoma skin cancer (39). Recent studies have 
shown promising results with respect to the evaluation 
of tumour thickness of BCC lesions (16, 27). However, 
non-invasive imaging techniques are so far experimental 
with respect to evaluation of skin tumours, and biopsy 
specimens for histopathological examination of BCC 
are still considered to be the reference standard.
A variety of histopathological BCC subtypes are 
described and their global distribution shows a predo-
minance of the nodular type, which most often appears 
on the head (40). In the present study, however, most 
Fig. 1. Bland-Altman plot showing difference between measurements by 
excision and punch biopsy, according to mean tumour thickness. The mean 
difference (bias) was 0.14 mm, with 95% limits of agreement at –1.3 and 
1.6 mm.
Fig. 2. Relationship between measurements of tumour thickness in 
corresponding punch biopsy and excision specimens. The shaded, grey area 
shows where excision depth exceeds punch biopsy depth with the line of 
identity at the border. The mean (–––) and 95% upper (- - -) prediction lines 
are superimposed.
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of the BCCs were of the superficial type and located 
on the trunk. It is possible that a number of patients 
with nodular facial tumours were primarily referred 
to the Department of Plastic Surgery, where advanced 
facial surgical procedures are performed at our hospital; 
consequently these patients would be unavailable for 
this study. Nodular tumours tend to grow deeper into 
cutaneous tissue than the superficial type (5, 40). With 
more nodular tumours included, lack of agreement 
might have been even worse.
Topical PDT is an effective treatment for superficial 
lesions and may also be considered in nodular lesions 
where alternative treatments such as surgery may be 
suboptimal (41). 
The present international PDT consensus guideline 
(26) does not recommend treating BCC tumours that 
are thicker than 2.0 mm. The taking of pre-treatment 
biopsy samples for assessment of tumour thickness is 
encouraged (42), and is currently a supportive diag-
nostic method often used in clinical practice to provide 
information and select tumours suited for PDT. 
However, two recent studies did not find any corre-
lation between pre-treatment BCC thickness and PDT 
treatment failure (43, 44). The hypothesis in one of these 
studies was that thickness measurements from biopsy 
specimens might not be representative for tumour thick-
ness of the entire lesion. This idea is supported by the 
findings in the present study, which question the ability 
of a single biopsy reliably to reflect tumour thickness. 
Even though a pre-treatment tumour thickness biopsy 
measurement of 1.0 mm suggests that the BCC tumour 
most likely will be within the current PDT consensus 
guideline recommendations of 2.0 mm, tumours that 
measure more than 1.0 mm on biopsy may well exceed 
this limit.
It should be noted, however, that the prediction inter-
val presented in Fig. 2 derives from a limited number 
of observations. 
The value of biopsy-based thickness measurements 
in BCC has, to our knowledge, not been presented pre-
viously. However, in a different type of non-melanoma 
skin cancer, a study of SCC of the lower lip (14), the 
relationship between biopsy with excision specimen 
tumour depths has been investigated. In this study a 
considerable disparity between corresponding measure-
ments were found; in particular for tumours more than 
3.0 mm thick. Together with the results from the pre-
sent study, it appears that a single pre-treatment biopsy 
measurement in thick lesions may prove insufficient for 
selection of treatment, and this should be acknowledged 
when deciding on individual patient management and 
with regard to research in this field.
In conclusion, we found reasonable overall agreement 
between punch biopsy and surgical excision measure-
ments of BCC tumour thickness when we compared 
the mean measurements of the two groups. A biopsy 
tumour thickness of 1.0 mm suggests that the tumour 
is likely to be within the current accepted limits for 
PDT. The paired measurements of individual lesions 
may, however, differ considerably, and this disparity 
increases with increasing tumour depth. 
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Summary
Background Prolonged follow-up data on topical photodynamic therapy (PDT) in
basal cell carcinoma (BCC) are necessary for a full evaluation of its effect and for
comparison with conventional treatment methods.
Objectives To assess 10-year long-term PDT efﬁcacy in primary and recurrent BCC
and to evaluate clinical and histopathological factors which may be associated
with treatment failure.
Methods We performed a longitudinal study on 60 histologically veriﬁed BCCs in
44 patients treated with curettage and one or two sessions of dimethylsulphoxide
(DMSO)-supported topical 5-aminolaevulinic acid (ALA)-based PDT. Treated
lesions were investigated by clinical and histopathological examination at regular
intervals. The main outcomes were 10-year lesion complete response rate using a
time-to-event analysis, histological treatment failure and cosmesis.
Results Overall complete response rate for all lesions was 75% (95% conﬁdence
interval 64–87%); 60% after one and 87% after two treatment sessions. The
response rate was 78% for primary lesions; 63% after one and 90% after two ses-
sions. The cosmetic outcome was rated as good or excellent in 91–100% of eval-
uated cases. Treatment failure was documented in 15 (25%) of 60 lesions;
clinical investigation identiﬁed 14 of them. All failures were noted within 3 years
of treatment. Male gender, recurrent tumour and one treatment session were fac-
tors signiﬁcantly associated with treatment failure. The only lesion larger than
2Æ0 cm relapsed.
Conclusions Two sessions of DMSO-supported topical ALA-PDT and curettage can
provide long-term effective treatment results with favourable cosmetic outcome
in primary, small BCC.
Basal cell carcinoma (BCC) is the most common cancer in
white people and its incidence is rising.1 It most often appears
on sun-exposed skin and can cause considerable local tissue
destruction and patient morbidity.2 Surgery and radiotherapy
appear to be most effective among a variety of interventions
available to treat BCC, with Mohs micrographic surgery show-
ing the lowest failure rates.3 Topical photodynamic therapy
(PDT) is an attractive and minimally invasive treatment option
in cases where surgery is considered suboptimal: in patients
with multiple comorbidities, high risk of postsurgical scarring
with or without functional impairment, large lesions, or
where cosmetic outcome is of major concern.4,5
The most commonly used topical precursors of photosensi-
tive porphyrins for PDT in BCC are 5-aminolaevulinic acid
(ALA) and methyl aminolaevulinate (MAL).6 PDT exerts its
action through light activation of the photosensitizer in the
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presence of oxygen, leading to the release of reactive oxygen
species that cause a selective destruction of the targeted atypi-
cal cells.7
Since the pioneer publication by Kennedy et al. in 19908
several studies have provided information on the effect of top-
ical PDT,6,9 with 5-year data showing long-term clearance
rates from 64% to 86% in BCC.5,10,11 Several strategies have
been explored to enhance the treatment effectiveness, particu-
larly when treating thicker tumours, as this therapy has lim-
ited skin-penetrating abilities.12,13 The use of
dimethylsulphoxide (DMSO), which is a drug penetration
enhancer, and the use of pretreatment lesion preparation can
improve treatment efﬁcacy.12,14
Using these strategies we have previously reported 6-year
ALA-PDT follow-up data showing an overall tumour clearance
rate of 81% among those lesions clinically observed to be in
complete response 3 months following treatment.15
Although this result adds to evidence supporting topical
PDT to be an effective treatment modality, several studies
have shown that results achieved using different treatment
methods will vary depending on the length of follow-up
time.16–19 With various traditional types of treatment,
evidence suggests that up to 18% of recurrent BCCs present
clinically between 5 and 10 years following therapy.16 Pro-
longed follow-up data are thus necessary for a full evaluation
of topical PDT as a treatment alternative to conventional
modalities for BCC.
The main objective of the present study was to assess 10-
year long-term treatment response and cosmetic outcome of
primary and recurrent BCC after DMSO-supported topical
ALA-PDT and curettage. A secondary aim was to explore clini-
cal and histopathological factors that may be associated with
treatment failure.
Materials and methods
Patients and lesions
Patients referred to the Department of Dermatology, St Olav’s
University Hospital, Trondheim from 1 September 1997 to 1
September 1998 with suspected BCCs were screened. Excluded
from treatment by topical PDT were patients under the age of
18 years, those who where pregnant or breastfeeding, or
those with Gorlin syndrome.
Excluded from the study were lesions clinically evaluated as
morphoeic or pigmented, lesions that had been treated within
the last 6 months, where the diagnostic biopsy was older than
6 months, or lesions with thickness in excess of 3Æ5 mm by
histology. Lesions without histologically veriﬁed diagnosis in
advance of treatment, or lesions that received more than two
PDT treatment sessions were also excluded.
The localization of all lesions was marked on a chart, and
lesions were photographed for later identiﬁcation of treatment
sites. Lesion size was estimated clinically as the mean value of
the greatest length and width and classiﬁed into three groups:
< 1Æ0, 1Æ0–2Æ0 and > 2Æ0 cm.
The study was approved by the regional committee for
medical research ethics (4.2008.2877) and patients gave writ-
ten informed consent.
Treatment procedure
From September 1997, two treatment sessions of curettage
and topical ALA-based PDT were performed 1–2 weeks apart.
From February ⁄March 1998, only one treatment session was
given.
Both physical and chemical PDT supportive measures were
used to enhance penetration of ALA into tumour tissue. All
lesions were pretreated with superﬁcial curettage with the
intention only to remove the upper part of epidermis on
visible tumour and about 4 mm beyond its margin. In add-
ition, careful intratumoral curettage (debulking) to reduce
tumour volume was performed occasionally, depending on
clinical assessment of tumour thickness. No local anaesthesia
was used. Following curettage, a small piece of gauze soaked
in DMSO 99% (Merck, Darmstadt, Germany) was applied to
the lesions located on trunk and extremities for 5 min. DMSO
is a chemical solvent which disrupts the skin barrier. An
emulsion of 20% ALA (Norsk Hydro, Oslo, Norway) and
Unguentum Merck (Merck, Hermal, Reinbek, Germany) was
then applied on to the treatment site. On lesions located on
face and hairy scalp DMSO 4% was added to the ALA-contain-
ing emulsion.
The treatment area was covered by a semipermeable dress-
ing. Residual emulsion was removed after 3 h in accordance
with former Norwegian ALA-PDT experience. The treatment
area was then exposed to light for about 8–10 min. A broad-
band halogen light source (Instrumentation Department, Nor-
wegian Radium Hospital, Oslo, Norway) was used, with an
emission spectrum of 550–700 nm and a light intensity of
150–230 mW cm)2 at the lesion surface.
Follow-up procedures
The post-treatment follow-up period was initially intended to
be 1 year, and was thereafter gradually prolonged. Patients
were followed up by dermatologists at the outpatient clinic at
3, 6, 12, 24, 36, 72 and 120 months after treatment. The
treated sites were evaluated by inspection and palpation and
classiﬁed as either complete response or as treatment failures.
Treatment failure comprised both lesions with initial 3-month
noncomplete response and lesions with recurrence of tumour
within or contiguous to the treatment area. Clinically
suspected treatment failures were conﬁrmed by histology. In
addition, all lesions in complete clinical remission were biop-
sied for histological examination at 12- and 36-month follow-
up. A 2 or 3 mm punch biopsy was used to obtain tissue
samples in all cases.
The cosmetic outcome was assessed by the investigator at 6,
12, 24, 36, 72 and 120 months and by the patients at 24, 36 and
72 months after therapy. The outcome was recorded on a four-
point ordinal scale as excellent (absence of any stigmata other
 2012 The Authors
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than scar formation after diagnostic punch biopsy) or as good,
fair or poor (presence of ﬁbrosis, atrophy or change of pigmenta-
tion, judged as slight, moderate or marked, respectively).
Histology
Pathologists at the Department of Pathology and Medical
Genetics, St Olav’s Hospital examined the diagnostic biopsy
specimens, which were routinely processed and stained with
haematoxylin, eosin and saffron. Tumour thickness was mea-
sured from below the stratum corneum to the base of the
tumour nest on the histologically prepared sections and classi-
ﬁed into three groups: < 1Æ0, 1Æ0–2Æ0 and > 2Æ0 mm. Retro-
spectively, the histopathological sections from the diagnostic
punch biopsies were re-examined by one pathologist. The
tumours were subclassiﬁed into nonaggressive and aggressive
growth types based on their histopathological growth pattern.
The nonaggressive category included the superﬁcial and nodu-
lar BCC types and the aggressive category included the micro-
nodular, morphoeiform and inﬁltrative types.
Data presentation and statistical analysis
Descriptive data are reported as numbers and ⁄or percentages.
Treatment failure or ‘cure’ (i.e. no treatment failure) was ﬁrst
tabulated according to relevant predictor variables disregarding
the time of recurrence, and analysed with v2 tests. Second, by
taking time into consideration, treatment failures were plotted
along the time axis as Kaplan–Meier plots; the steps were
drawn at the time when tumour recurrence was noted and
registered by the dermatologist.
Univariate analysis was done using the log rank test, and a
Cox proportional hazard model was ﬁtted using a backward
approach until only signiﬁcant predictors were retained in the
model. In the Cox model, the event time for detection of
treatment failure was set to midway between the previous (no
recurrence noted) and the follow-up visit when recurrence of
tumour was identiﬁed. The analysis was adjusted for clustering
of lesions within patients. P < 0Æ05 was considered statistically
signiﬁcant. Analysis was done using the package survival using
the statistical software R version 2.12.20
Results
Forty-four patients (22 men, 26 lesions; 22 women, 34 le-
sions) with 60 BCC lesions were followed. The mean age at
entry was 72 years (range 35–91). A variable number of
patients attended the scheduled appointments, but all patients
except those who died and those who had experienced treat-
ment failure were examined at the 72- and 120-month fol-
low-up visits (Fig. 1).
Thirty-four patients had one lesion, eight patients had two
and two patients presented each with ﬁve lesions. Five lesions
represented recurrences after previous treatments: four after
surgery and one after cryotherapy. The mean size was 0Æ7 cm
(range 0Æ2–2Æ1); only one lesion was larger than 2Æ0 cm. Of
35 lesions located to face, head and neck area, 31 were
< 1Æ0 cm and the remaining four were < 1Æ5 cm in size.
Twenty-ﬁve lesions received one treatment session and 35 le-
sions were treated twice. Further information on lesion base-
line clinical and histopathological characteristics is shown in
Table 1.
Fig 1. Flow of patients and lesions.
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Treatment evaluation
Ten years following PDT the overall BCC complete response
rate was 75% [95% conﬁdence interval (CI) 64–87%]. The
rate was 60% after one treatment and 87% after two treatment
sessions (Fig. 2). For primary lesions only, the response rate
was 78% (95% CI 68–90%); 63% after one and 90% after
two treatment sessions.
Treatment failure was documented in 15 of the 60 (25%)
treated lesions; in 10 of 25 (40%) after one and in 5 of 35
(14%) after two treatment sessions. BCC was identiﬁed at the
scheduled follow-up visits at 3, 6, 12, 24 and 36 months in
5, 2, 4, 2 and 2 treated sites, respectively. Histopathological
examination revealed one case of tumour residue that was not
captured by clinical investigation at 12 months follow-up. The
cosmetic outcome was rated as excellent or good by the inves-
tigator in 91%, 97%, 97%, 100% and 100% of cases at the
follow-up visits at 12, 24, 36, 72 and 120 months, respec-
tively. The patients rated the cosmetic outcome as excellent or
good in all cases.
In the log-rank univariate analyses, the clinical factors male
gender (P = 0Æ0046), recurrent tumour (P = 0Æ0047) and
number of treatment sessions (P = 0Æ0317) were associated
with treatment failure. Similar results were obtained from the
multivariate Cox model (male gender P = 0Æ020, recurrent
tumour P = 0Æ00024, treatment sessions P = 0Æ0030). Treat-
ment failure was identiﬁed among men in 11 of 26 (42%)
lesions and among women in 4 of 34 (12%) lesions
Table 1 Lesion baseline characteristics and lesion response to photodynamic therapy
Characteristics
Baseline Treatment failure
P-valuea
All lesions
(n = 60), n (%)
Primary lesions
(n = 55), n (%)
All lesions
(n = 15), n (%)
Primary lesions
(n = 12), n (%)
Gender
Male 26 (43) 22 (40) 11 (42) 8 (36) 0Æ016
Female 34 (57) 33 (60) 4 (12) 4 (12)
Age (years)
£ 71 30 (50) 30 (55) 6 (20) 6 (20) 0Æ55
> 71 30 (50) 25 (45) 9 (30) 6 (24)
Immune status
Immunocompetent 54 (90) 50 (91) 13 (24) 11 (20) 0Æ79
Immunosuppressed 6 (10) 5 (9) 2 (33) 1 (20)
Treatment sessions
1 session 25 (42) 24 (44) 10 (40) 9 (38) 0Æ036
2 sessions 35 (58) 31 (56) 5 (14) 3 (10)
Light dose (J cm)2)
75 46 (77) 43 (78) 12 (26) 10 (23) 1
100 14 (23) 12 (22) 3 (21) 2 (18)
Size (cm)
< 1Æ0 47 (78) 44 (80) 10 (21) 9 (20) 0Æ16
1Æ0–2Æ0 12 (20) 10 (18) 4 (30) 2 (20)
> 2Æ0 1 (2) 1 (2) 1 (100) 1 (100)
Location of tumour
Face, head, neck 35 (58) 31 (56) 11 (31) 9 (29) 0Æ23
Trunk 19 (32) 18 (33) 4 (21) 3 (16)
Extremities 6 (10) 6 (11) 0 0
H-zone
Inside H-zone 22 (37) 20 (36) 7 (32) 7 (35) 0Æ54
Outside H-zone 38 (63) 35 (64) 8 (21) 5 (14)
Histological pattern
Superﬁcial 14 (24) 14 (26) 2 (14) 2 (17) 0Æ47
Nodular 28 (47) 25 (46) 9 (32) 7 (28)
Aggressive 17 (29) 15 (28) 4 (24) 3 (25)
Lesions included, n 59 54
Tumour thickness (mm)
< 1Æ0 27 (47) 27 (51) 5 (19) 5 (19) 0Æ23
1Æ0–2Æ0 20 (34) 15 (28) 8 (40) 5 (33)
> 2Æ0 11 (19) 11 (21) 2 (18) 2 (18)
Lesions included, n 58 53
All lesions = primary and recurrent lesions. aThe P-values refer to v2 tests of the cross-classiﬁcation of the given characteristics and outcome
among all lesions (e.g. for gender: 11 failures out of 26 in men vs. four out of 34 in women, P = 0Æ016).
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(Table 1). Of the ﬁve recurrent tumours included, treatment
failure was observed in three (60%) within 3 months follow-
ing PDT. None of the other clinical or histopathological factors
was found to be signiﬁcantly associated with treatment failure
(Table 1).
Discussion
The present study demonstrated a high and sustained 10-year
PDT efﬁcacy of 87% in BCC receiving two treatment sessions,
and a 90% complete response rate shown in primary tumours.
This is comparable with long-term results after conventional
nonsurgical therapies.16,19,21 However, it is difﬁcult to compare
different therapies because of lack of uniformity in study design
such as inclusion criteria and different statistical methods.21
In the present study, for best approximation of true
response rates, a time-to-event approach was chosen to esti-
mate lesion response rate over time.19 Treatment outcome was
assessed at the follow-up visits and recorded either as com-
plete response or treatment failure. The reported response
rates include the residual tumours we observed 3 months after
treatment that in many other PDT studies are not counted as
failures.22
At follow-up, histopathological investigation revealed treat-
ment failure in only one case that was missed by clinical
assessment. We cannot rule out that sampling error may be a
problem as histopathological specimens were obtained using
small (2 or 3 mm) punches not necessarily representative for
the complete lesion.
Treatment efﬁcacy was signiﬁcantly higher in primary le-
sions receiving two treatment sessions compared with those
receiving only one. This ﬁnding supports the current accepted
practice of two PDT sessions in the treatment of BCC.6,9 How-
ever, as the lesions (patients) were not randomized with
respect to the given number of treatment sessions, this result
should be evaluated with caution as selection bias cannot be
ruled out. One may still argue that this allocation was ‘ran-
dom’, in the sense that it depended on when treatment was
given: early or mid-way through the treatment period. Guide-
lines on optimal number of PDT treatment sessions were not
available in 1997. The initial practice of using two treatment
sessions when the method was ﬁrst introduced to our depart-
ment was later reduced to one session, as we obtained more
experience with the technique.
The present study reﬂects ‘real life’ in the sense that few
exclusion criteria were used and even recurrent (failure of
previous treatment) lesions were included. Recurrent BCCs are
known to have an increased risk of relapse, with 5-year long-
term recurrence rates between 10% and 40% after treatment
with various non-Mohs modalities.17 These are more often of
Fig 2. Probability of lesion complete response over time. The ‘steps’ are drawn at the visit when recurrence was noted by the treating
dermatologist. CI, conﬁdence interval; PDT, photodynamic therapy.
 2012 The Authors
BJD  2012 British Association of Dermatologists 2012 166, pp1342–1348
1346 Prospective 10-year follow-up study of PDT in BCC, E. Christensen et al.
the histological aggressive subtype and considered high-risk
tumours.2 Reports on topical PDT efﬁcacy of recurrent BCC
are scarce. However, in a 3-year follow-up after topical PDT
of 11 recurrent BCCs the cure rate was estimated to 63%.23 In
the present study the cure rate did not exceed 40% but only
ﬁve lesions were evaluated. Noninvasive therapeutic methods
are currently not regarded as a ﬁrst-line treatment for these
cases.17
Apart from our 6-year follow-up study of the same cohort,
we are not aware of other studies suggesting that men have a
greater propensity for recurrence of BCC after PDT.
BCC incidence is reported to be higher in men than in
women,1,3,24 male gender is found to be predictive of exten-
sive subclinical tumour spread,25 and BCCs in men have been
reported to possess a propensity towards deeper invasion than
those in women.26 Some studies found that men have an in-
creased tendency to experience tumour recurrence than
women after Mohs micrographic surgery or radiotherapy.27,28
The reason for these ﬁndings has not been established. BCC is
a follicular tumour and it has been speculated that the more
prominent male hair follicles may contribute to deeper BCC
growth into tissue.26
Several BCC characteristics are known to be associated with
higher recurrence rates including tumour thickness, subtype,
size and location, particularly to the mid-face area
(H-zone).22,29 In the present study no signiﬁcant association
was found between recurrence and these factors. PDT for
treatment of > 2Æ0 mm thick BCC and for aggressive growth-
type tumours achieved a good outcome compared with the
results in thinner lesions and in tumours considered to be of a
more low-risk growth type. Most lesions were small. The only
lesion larger than 2Æ0 cm resulted in treatment failure, but no
ﬁrm conclusion based on this single ﬁnding can be made. A
higher percentage of tumours within the H-zone recurred
compared with tumours located to face, head and neck area
outside this zone, but the difference was not statistically sig-
niﬁcant. However, the size of the study population limits the
value of subgroup analyses.
In a systematic review by Rowe et al. the cumulative recur-
rence rate following surgery, radiotherapy and curettage and
desiccation in BCC showed 50% of recurrences within 2 years
and 66% appearing within the ﬁrst 3 years of treatment.16 In
addition, 18% of recurrences were found to appear as late as
between the 5th and 10th year.
Current long-term follow-up data after PDT also demon-
strate that BCC recurrence rate increases with prolonged fol-
low-up time: no-recurrence reported to be 93–97% at
3 months, decreasing to 64–81% at 5–6 years following treat-
ment.5,10,11,15 However, it appears that most recurrences after
PDT occur during the ﬁrst years after treatment. In a random-
ized study comparing MAL-PDT with surgery with 5-year
follow-up, more than 80% of treatment failures appeared
within 2 years and no recurrence of BCC was noted after
3 years follow-up.5 Similar results were found at 5-year
follow-up of a randomized study comparing PDT using MAL
with cryotherapy. Most treatment failures were identiﬁed
within the ﬁrst 2 years after PDT and no recurrences were
observed after 3 years in the PDT group.10 Most tumour
recurrences were also detected within 2 years following treat-
ment in a randomized study comparing ALA-PDT with surgery
in 173 nodular BCCs. In this long-term study, all recurrences
except one appeared within 3 years after PDT.30 Also in a
smaller ALA-PDT based study treating 15 BCCs, three of four
treatment failures appeared within 3 years after treatment and
the fourth appeared between the 3- and 6-year follow-up vis-
its.11 In the present study, as many as 87% of all treatment
failures appeared within 2 years and no failures were observed
beyond 3 years following treatment.
Both topical ALA- and MAL-PDT are proved to be effective
in BCC.6,9 Despite MAL being more selectively taken up into
tumour tissue than ALA,31 there is no evidence, at present,
that MAL-PDT is more efﬁcient in the treatment of nonmel-
anoma skin cancer. However, PDT procedures are currently
not standardized, making an exact comparison of results
between various studies difﬁcult.
The present study demonstrated a particular high cure rate
in primary tumours receiving two treatment sessions. The use
of DMSO may have contributed to the favourable result.
DMSO has been shown to initiate ALA-induced porphyrin
production32 and to enhance ALA-PDT effect in BCC.33 Pre-
treatment lesion preparation may further have contributed to
the favourable outcome, by also including the perilesional area
to minimize the risk of recurrence from subclinical tumour
extensions.34 In accordance with our national PDT practical
guidelines,35 this curettage was aimed at gently removing the
upper epidermis to facilitate the skin penetration of ALA with-
out compromising the cosmetic outcome. This was rated as
excellent or good in 100% of all evaluated cases at both the
6- and 10-year visits.
In conclusion, two sessions of curettage and DMSO-
supported topical ALA-PDT provide a long-term effective and
cosmetically favourable outcome in primary, small BCC. Most
treatment failures appear within 2 years of treatment.
What’s already known about this topic?
• Evidence suggests that treatment results will vary
depending on the length of follow-up time, and up to
18% of recurrent basal cell carcinomas (BCCs) occur 5–
10 years following conventional treatments.
What does this study add?
• The outcome after two sessions of topical dimethyl-
sulphoxide-supported 5-aminolaevulinic acid-based pho-
todynamic therapy and curettage, showing a 10-year
cure rate of 90% in primary, small BCCs, with all recur-
rences appearing within 3 years of treatment, is compa-
rable with results of other well-accepted nonsurgical
therapies.
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